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Abstract: Clinical and Molecular Determinants of Malignant Transformation in 
Oral Epithelial Dysplasia 
Known risk factors for malignant transformation in oral lesions with malignant potential 
include the size and appearance, however the importance of site, grade of dysplasia and 
exposure to environmental carcinogens remains controversial.  Patients with a diagnosis of 
oral epithelial dysplasia (OED) were recruited to a longitudinal observational cohort study in a 
tertiary oral dysplasia clinic. Clinical, histopathological and risk factor data were assessed to 
identify clinical determinants of malignant transformation; in patients where the oral 
dysplasia underwent malignant transformation the treatment outcomes were evaluated. 
Ninety-eight eligible patients were recruited and followed up for the median duration of 48 
months. Twenty-six (26.5%) patients underwent malignant transformation, with significant 
predictors as follows: non-smoking status, lateral tongue subsite, non-homogeneous 
appearance, high histological grade and size of lesion >200mm2.  Whilst these clinical 
features have previously been associated with malignant transformation in OED, the highly 
statistically significant finding of malignant transformation in non-smokers, consistent with 
several cohorts reported in the recent years.  This suggests that these patients, apparently 
with endogenous OED, perhaps with inherited or acquired predisposition, are considered to 
be at higher risk (compared to smokers) and should form the focus for further investigation. 
All 26 patients in whom dysplasia transformed to oral squamous cell carcinoma were 
presented to the multidisciplinary team (MDT) with stage 1 disease. Ninety-one percent 
(21/23) were initially treated by wide local excision and 9% (2/23) required tumour resection 
followed by reconstruction. Twenty-two percent (5/23) of patients developed second primary 
OSCC, and further diagnoses of oral dysplasia with an estimate that 76% of patients will 
undergo one or more event in 5 years. Specialist monitoring of OED by a multidisciplinary 
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team allows detection of OSCC at an early stage, facilitating largely curative treatment with 
simple and usually minor surgical intervention. The high incidence of second primary OSCC 
formation in high risk patients with OED supports an intensive targeted surveillance regimen 
in this group of patients.  
The observed higher rate of malignant transformation in non (or light)-smokers supports the 
hypothesis of an endogenous aetiology. It is hypothesised that loss of FANCD2 and associated 
proteins lead to genomic instability and oncogenesis. 
Longitudinal archival samples were obtained from 40 individuals with OED from time of 
diagnosis to the most recent clinical review in 23 non-transforming/stable OED or until 
excision of the SCC in 17 unstable OED undergoing malignant transformation. 
Histopathological reassessment, immunohistochemistry for FANCD2 and Western blotting for 
phosphorylation/mono-ubiquitination status of ATR, CHK1, FANCD2 and FANCG were 
undertaken on each tissue sample. 
Immunohistochemistry studies found under-expression of FANCD2 was observed in the 
diagnostic biopsy of OED lesions which later underwent malignant transformation when 
compared with stable OED.  Combining the FANCD2 immunohistochemistry scores with 
histological grading more accurately predicted malignant transformation (p=0.005) than 
histology alone and correctly predicted malignant transformation in 10/17 initial biopsies. A 
significantly reduced expression of total FANCD2, pFANCD2, pATR, pCHK-1 and pFANCG were 
observed in OED which underwent malignant transformation.  
There is strong evidence that defects in the DNA damage sensing-signalling-repair cascade 
are associated with malignant transformation in OED. Loss of post-translational modification 
in FANCD2 and related proteins, was more predictive of malignant transformation when 
compared to clinical parameters.  
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Chapter 1 Introduction: Challenges in the management of oral 
epithelial dysplasia and the role of the Fanconi Anaemia Pathway in 
oncogenesis 
 
Introduction 
Oral epithelial dysplasia falls within the group of oral lesions with malignant potential. The 
diagnosis is achieved after histopathological assessment following biopsies of oral lesions 
which can vary in appearance: homogenous white patch (leukoplakia), red patch 
(erythroplakia), non-homogenous lesion (erythroleukoplakia) or an erosive or ulcerated 
lesion. The management of oral epithelial dysplasia is clinically important as it offers the 
clinical team the opportunity to detect any progression in the grade of dysplasia or more 
importantly malignant transformation. Despite advances in the management of oral cancer, 
the main determinant in survival outcomes of treatment is primarily dictated by the stage of 
oral cancer(1). In tumours which evolve within a step-wise progression model through oral 
epithelial dysplasia before malignant transformation, timely intervention combined with 
close clinical surveillance offers the opportunity to optimise survival and functional outcomes 
whilst utilising simpler treatment modalities i.e. surgery as single modality often without the 
need for combined modality (adjuvant radiotherapy or chemoradiotherapy). 
 
Classification of oral epithelial dysplasia 
The main classification utilised is the 2017 World Health Organisation (WHO) classification 
where the severity of dysplasia is graded mild, moderate or severe(2). The binary system(3) 
of low and high grade dysplasia, which was devised  to improve clinical decision making and 
reduce variation of reporting amongst pathologists, has been included as one of the 
recognised classification systems for oral epithelial dysplasia in the 2017 WHO classification. 
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Several other less commonly utilised systems include the classifications suggested by Banoczy 
and Csiba(4), Lumerman et al.(5), Speight et al.(6), Kuffer and Lombardi (oral intraepithelial 
neoplasia)(7), and Brothwell et al(8). Malignant transformation of oral leukoplakia has been 
reported as occurring in 0.13-17.5% (9, 10) of cases, over a period of 6 months to 30 years; 
this wide range is likely to be due to differences in patient groups, length of follow up and 
treatment modality between studies.  It is an interesting observation that, in population 
studies, 20.1-42.5% of untreated leukoplakia resolved in 5 years(11). Non-homogenous 
lesions are more likely to undergo malignant transformation (9, 10) and up to seven-fold 
increase in malignant transformation risk has been reported (12, 13).  Around 90% of 
erythroplakia showed evidence of severe dysplasia or carcinoma on histology(14).  The wide 
difference in outcome indicates the need for histological diagnosis (as opposed to clinically 
descriptive terms such as leukoplakia or erythroplakia, which could encompass a wide range 
of diagnoses). 
 
Challenges in the management of oral epithelial dysplasia 
Clinicians face several challenges in the management of oral epithelial dysplasia: 
1. The number of patients with oral dysplasia managed within secondary care is 
relatively small and when managed by multiple clinicians from different specialties 
e.g. oral and maxillofacial surgery, oral medicine, oral surgery or otolaryngology, 
indications and thresholds for intervention can vary. The need for involvement of 
multidisciplinary team members i.e. Oral and Maxillofacial Surgery, Oral Medicine, 
Oral Pathology, Oral Surgery and Biomedical Scientists has been adopted in teaching 
institutions, however such a set-up can be perceived as resource intensive and might 
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not be readily available to many secondary care units receiving primary care referrals 
for such conditions(15). 
2. The clinical appearance of oral epithelial dysplasia is similar to various oral lesions e.g. 
hyperkeratosis, lichenoid reaction, lichen planus or early oral cancer. 
3. The evidence for interventions and treatment remain low level despite the decades of 
experience and increasing number of publications in the literature(16): 
a. A considerable number of publications still utilise to the term or diagnosis of 
leukoplakia (or erythroplakia) as the main representation of oral epithelial 
dysplasia, making extrapolation of findings difficult and limits the 
generalisability of the reported findings in contemporary practice within a 
secondary or tertiary setting(17-19),  
b. Most of the published literature report case series with limited numbers from 
single centres(4, 20-22), 
c. The severity of the grade of dysplasia is does not correlate consistently with 
the clinical behaviour of the oral dysplasia in terms of malignant 
transformation and 
d. Although there are clinical features which could be correlated to a higher risk 
for malignant transformation, this can vary depending of the population 
studied and perhaps could be influenced by regional endogenous or 
environmental factors. 
4. Most studies aimed at identifying a molecular or pathological marker of malignant 
change have failed to undertake correlation with longitudinal clinical outcomes, so 
their translational value has been diminished leading to the lack of clinical application 
(23-25). Furthermore, most of the reported studies correlate more with the severity 
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of the grade of dysplasia(26-28) rather than malignant transformation and this 
approach is difficult as event rate of malignant transformation is low, and studies are 
therefore prolonged(20). 
5. The progression of oral epithelial dysplasia to malignancy can take several years (up 
to 10-15 years). This low event rate makes time-defined clinical trials utilising 
malignant transformation as an end-point less feasible for funding. There is a notable 
paucity of multi-centred/collaborative protocols, and where malignant transformation 
can be predicted there remains some uncertainty about recommended treatment 
options. 
6. The duration of follow-up for oral epithelial dysplasia remains a subject which 
generates controversy(20). In a resource constrained climate, the clinical justifications 
for review of a benign condition needs to be evidence-based. Similar challenges have 
been faced by gastroenterologists managing Barrett’s oesophagus, where patients 
with the estimated risk of malignant transformation of 0.5% per annum undergo 
interval surveillance by endoscopy of the upper gastrointestinal tract(29). 
 
The Fanconi Anaemia Pathway and oncogenesis 
 
Several cancer systems, including head and neck squamous cell carcinomas have been found 
to have dysregulation of the Fanconi Anaemia (FA) pathway(30) The incidence of head and 
neck squamous cell carcinoma (HNSCC) in patients with the cancer prone syndrome, Fanconi 
Anaemia, is up to 1400 times that of the general population (31-33) and occurs earlier in life. 
The Fanconi Anaemia pathway (FAP) facilitates homologous recombination repair of DNA 
double-strand breaks and is an integral component of the DNA damage repair mechanism 
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which maintains genomic stability in healthy individuals (34, 35). Defects in the FA pathway 
leads to increased cancer susceptibility(30). FA is a rare genetic condition, whereby there is a 
defect in the DNA repair mechanism due to a mutation in a FA gene(36), resulting in bone-
marrow failure, developmental abnormalities and increased cancer susceptibility due to 
cellular sensitivity to cross-linking agents(35). Higher risks of developing cancers such as 
acute myeloid leukaemia and squamous cell carcinoma have been observed in at least 20% of 
FA patients(32, 37). The incidence of oral leukoplakia in FA patients who have not undergone 
haematopoietic stem cell transplant is reportedly high and it has been suggested that this 
should be included as part of the phenotype of this group of patients and screening for oral 
leukoplakia should form part of the regular surveillance strategy due to the high risk of head 
and neck (oral) cancer(38). 
The FA pathway is a DNA repair pathway, which responds to DNA damage including 
errors during replication or DNA cross-linking agents such as diepoxybutane, mitomycin C and 
cisplatin(39). Diepoxybutane/mitomycin C stress test based on the increased chromosomal 
instability seen in FA cells, compared to normal controls, remains the front-line diagnostic 
test. Cisplatin is a first-line chemotherapeutic agent in primary non-surgical management of 
head and neck cancer. The status of the FAP has been identified as a potential major 
predictor of response to treatment with cisplatin (as a radiation sensitizer) when utilised with 
radiotherapy in the treatment of head and neck cancer(40). The FAP consists of at least 22 
proteins and has 3 main components (41) (Figure 1.1): (i) the core complex which consists of 
proteins FANCA, B, C, E, F, G, L and M, the main role of which is to facilitate ubiquitination of 
(ii) FANCD2 and FANCI protein dimers which then activate (iii) five downstream effector 
proteins (FANCJ, BRCA1, RAD51, FANCN and FANCD1/BRCA2) that directly participate in DNA 
damage repair(30). Within the overall DNA damage response, the FAP interacts with the DNA 
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damage sensing and signalling proteins, ataxia telangiectasia rad–3 (ATR), ataxia 
telangiectasia mutated (ATM) and checkpoint 1 (Chk1) kinases (42, 43). Major sites of ATR-
mediated phosphorylation are found on FANCA, FANCD2, FANCG and FANCI (44-47).  
Mutations or disruptions in any of these FANC proteins can lead to chromosome instability 
and cross-linker hypersensitivity(30) .  
 
 
 
 
 
During interphase of the cell cycle, any DNA damage that occurs stimulates the assembly of  
Figure 1. 1 Activation of the Fanconi anaemia pathway. DNA damage such as interstrand 
cross-links can cause the replication fork to stall, creating single-stranded regions coated by 
RPA. This leads to activation of the checkpoint kinase ATR and its downstream effector kinase 
CHK1. ATR and CHK1 phosphorylate several components of the Fanconi anaemia (FA) core 
complex and the FANCI–FANCD2 (ID) complex. Phosphorylation of FANCI (solid red circles) 
may act as a switch, making the ID complex ready for ubiquitination. Phosphorylation of 
FANCD2 and Fanconi anaemia core components (broken pink circles) affects the efficiency of, 
but is not essential for, ID ubiquitination by the FA core complex, together with E1 and 
UBE2T. Analogously, ubiquitination of FANCD2 (solid orange ovals) is essential for DNA repair, 
activating the ID complex for chromatin binding; on the other hand, FANCI ubiquitination 
(broken orange oval) affects the efficiency of, but is not essential for, DNA repair. FANCM 
also has a direct role in DNA repair, as a branch point translocase for stalled replication forks 
and four-way junctions(48). Reproduced with permission from the author and publisher: A 
major switch for the Fanconi anemia DNA damage–response pathway. Weidong Wang. 
Nature Structural and Molecular Biology 2008. 15(11) 1128-9. 
 
FANCD2 (or FANCD2/FANCI heterodimer) activates the DNA repair pathway once it has been 
phosphorylated and monoubiquitinated (S331 and K561 respectively) (49). Homologous 
recombination is the main method of DNA damage repair that the FA signalling pathway 
selects. However, in FANC deficient cells, attempted repair of lesions occurs through the 
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error-prone repair process of nonhomologous end joining (NHEJ). This method increases the 
chances of mutagenesis occurring in FANC deficient cells(37) (Figure 1.2). 
 
 
 
Figure 1. 2 Fanconi pathway safeguards chromosomal stability in the repair of inter-
strand crosslinks by facilitation of homologous recombination repair and suppression of non-
homologous end joining (NHEJ). 
 
 
The activation of the FANC proteins, which are part of the FA pathway, is brought about by 
CHK1 (checkpoint kinase) phosphorylation by ATR (Ataxia–telangiectasia and Rad3–related) 
kinase, which in turn phosphorylates the FANC proteins (Figure 1.1). CHK1 is a checkpoint 
kinase that regulates FA cells at the G2/Mitosis checkpoint in the cell cycle(30). DNA damage 
that causes stalled replication fork progression leads to ATR kinase activation of CHK1; CHK1 
responds by phosphorylating Cdc25c which halts the transition of the cells from G2 into 
mitosis. FA tumour cells mainly acquire DNA damage during the S phase of the cell cycle, 
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when DNA repair through the FAP occurs in non-FA cells(30, 50). ATR phosphorylates CHK1 
whereas ATM (ataxia-telangiectasia mutated) phosphorylates CHK2. ATM is part of a DNA 
repair pathway that runs parallel to the ATR pathway(35). ATM works with ATR to repair 
double-strand breaks in DNA in NHEJ. ATR phosphorylates several proteins: 
CHK1, FANCA, FANCI, FANCD2 and FANCG. The phosphorylation of CHK1 by ATR then leads to 
the activation of FANCE(43, 51, 52). Both CHK1 and CHK2 phosphorylate the FANCD2 protein 
at different sites, however phosphorylation of one site (S331 – serine residue at position 331) 
is essential for activation(43). The ATR pathway is of interest because when CHK1 is 
phosphorylated it in turn phosphorylates FANCD2 leading to ‘activation’ of the protein and 
the downstream processes in DNA damage repair. Previous studies have shown that the site 
of phosphorylation of the FANCD2 protein is S331(43). Another functional post translational 
modification of interest is the phosphorylation site located at S7 in FANCG, as this has been 
shown to be important in optimal homologous recombination repair(53). Therefore, these 
post-translational modifications can be used as indicators for the activation of the FA-DNA 
repair pathway. Such post-translational modifications can be detected by using antibodies 
against phosphorylated states of the FANC proteins.   
In evaluating the activation of the FA pathway, the FANCD2 (or FANCI) protein can be used as 
an indicator of FA pathway status(49). FANCD2 is both monoubiquitinated and 
phosphorylated in response to DNA damage. It has been observed that the process leading to 
early occurrence of oral cancer in FA patients follows a similar pathway as in non-FA cancer 
patients, which would support a caretaker function for FA genes in the protection against oral 
carcinogenesis(54). It is therefore hypothesised that failure to activate FANCD2 and/or 
related proteins would be observed in the OED samples which subsequently underwent 
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malignant transformation. These phosphorylated sites could potentially be utilised as 
predictive indicators in oral epithelial dysplasia, in conjunction 
with clinical and histological assessment to determine whether malignant 
transformation is likely to occur. This could enable personalisation of patient management, 
supporting the decision for clinical intervention or observation.  
 
Aims of thesis 
 
• Identify the clinical determinants of malignant transformation in OED for patients 
managed in the Merseyside Tertiary Oral Dysplasia Multidisciplinary Team (MDT) 
clinic in Liverpool Dental Hospital, 
• Evaluate treatment outcomes of oral squamous cell carcinoma (OSCC) which has 
arisen from OED in the cohort of patients managed within the Oral Dysplasia MDT 
clinic in Liverpool Dental Hospital, 
• Identify the best surgical technique employed in the management of oral epithelial 
dysplasia in contemporary management of OED in contemporary clinical practice, 
• Establish a rational MDT approach in the management of OED, to personalise 
management algorithm and ensure effective utilisation of resource with the National 
Health Service (NHS), 
• Investigate the status of the Fanconi Anaemia Pathway in OED and this impacts on the 
risk of malignant transformation and 
• Propose future areas of research and innovation in clinical practice which will enable 
a personalised approach in the management of OED. 
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Objectives of thesis 
 
• Identify patients have been prospectively recruited into a molecular biomarker study 
(Sefton Research and Ethics Committee ethical approval Reference number: EC 47.01) 
and collate their clinicopathologic data and management outcomes in the Oral 
Dysplasia MDT clinic through their medical records, 
• Identify the clinical risk factors, from clinical outcomes data, for malignant 
transformation in patients with OED and establish the rate of malignant 
transformation in this cohort of patients, 
• Compare the clinical determinants of malignant transformation in OED in this cohort 
against the published evidence in the literature to ascertain the clinical relevance and 
inform future practice,  
• Investigate the treatment outcomes (treatment modalities, locoregional recurrence 
and survival) of patients with OED which have undergone transformation to OSCC and 
compare their treatment outcomes with patients who have presented with OSCC 
seen through the fast track suspected cancer pathway (i.e. OSCC which has arisen de-
novo), 
• Review the published literature for published series of surgical management of OED 
with laser excision and/or ablation, evaluate their treatment outcomes to inform best 
evidenced clinical practice with regard to their impact on malignant transformation in 
OED, recurrence of OED, how these techniques impact on tissue archiving initiatives 
and their medicolegal implications,  
• Provide clinical expert guidance in areas of importance in clinical practice i.e. 
diagnosis, indications for intervention and surveillance protocols, based on the 
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findings above and decades of cumulative experience within the Oral Dysplasia MDT 
members, with proposal for a clear strategy in the management of OED, 
• Access archival formalin fixed tissue of patients with OED for immunohistochemical 
expression of FANCD2 protein and extract proteins from these tissue blocks to 
investigate the status of activation of the FAP-DNA damage repair pathway in these 
patients, 
• Report on the findings of the translational work conducted in a subgroup of patients 
from the clinical outcome cohort to clarify the status and role of the Fanconi Anaemia 
Pathway and related proteins in malignant transformation of oral epithelial dysplasia 
and 
• Summarise the findings of this thesis and contextualise them within the current 
landscape of clinical practice and policies for future development in the NHS, within 
the framework of recommendations by the Royal College of Surgeons of England.  
Statement of hypothesis 
 
It is therefore hypothesized that in OED which has undergone malignant transformation, in 
the absence of environmental risk factors, an endogenous drive exists which leads to 
carcinogenesis and this we propose is a defect in the Fanconi Anaemia and its related 
pathways. 
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Chapter 2 The clinical determinants of malignant transformation in 
oral epithelial dysplasia  
Introduction 
 
The clinical significance of oral epithelial dysplasia (OED) lies in its association with malignant 
transformation into oral squamous cell carcinoma (OSCC)(55). OED can present clinically as 
leukoplakia: homogenous(flat, thin, uniform white) and  non-homogenous(white and 
red/erythroleukoplakia, speckled or nodular, verrucous leukoplakia)(56), or erythroplakia(57).  
OED can only be diagnosed histologically and in the WHO 2017(2) it is divided into mild, 
moderate, severe and carcinoma-in-situ, although it represents a spectrum of epithelial 
change rather than distinct categories. In order to reduce interobserver variability and 
improve clinical correlation, a binary system(58) has been suggested: low-risk (mild & 
moderate dysplasia) and high-risk (severe dysplasia and carcinoma-in-situ).  The risk of 
malignant transformation has been reported to be between 6.6-36.4%, systematic review 
and meta-analysis found the rate to be 12.1%(5, 9, 20, 59, 60).  Risk factors associated with 
malignant transformation include: female gender(10), longer duration of lesion(9, 18), 
idiopathic leukoplakia(non-smokers) (9, 18, 61), subsite of tongue and/or floor of mouth(61-
64), size >200mm2(21, 56, 65), non-homogenous appearance(9, 21), higher grade of 
dysplasia(10, 20, 66), verrucous subtype(5, 9, 67, 68) and the presence of multiple 
lesions(69). Surgical excision(including laser) has been the preferred modality of treatment in 
the management of OED(70), despite the lack of randomized controlled trial evidence(16) 
and recurrence rates of up to 35% have been reported(18). However, lesions that were not 
excised demonstrated a higher rate of malignant transformation compared with those that 
were excised(20, 71). Most of the reported literature have presented outcome data on oral 
leukoplakia/premalignant lesions, with only a few reporting clinical outcomes of OED(5, 59, 
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61, 62, 66, 71, 72). The purpose of this study was to evaluate the clinical factors that 
determined the risk of malignant transformation of OED into OSCC in a tertiary Regional Oral 
Dysplasia Clinic. 
Patients and methods 
Inclusion criteria 
Patients who attended the oral dysplasia clinic with lesions clinically suspicious of OED were 
prospectively recruited into a clinical and molecular biomarker study since September 1999 
and their demographic and pathology details were entered into a computerised database. 
Ethical approval for this study was given by Sefton REC (now North West – Liverpool Central; 
reference number: EC 47.01). Consent was obtained for retrospective and prospective 
analysis of tissue samples and clinical records. The principal inclusion criteria were biopsy 
proven OED or proliferative verrucous leukoplakia (PVL).  Any patient with a history of oral 
squamous cell carcinoma (OSCC), less than 2 years preceding or coincident, with OED was 
excluded. 
Data collection   
The following baseline information were recorded:  demographic details (age, gender), 
smoking and alcohol history, site and clinical appearance of lesion (homogenous or non-
homogenous), approximate size of lesion (measured as total surface area from clinical 
photographs, as documented in medical records or measurement of specimen when lesion 
was surgically excised),  number of lesions (single or multiple), histopathological diagnosis of 
initial biopsy, history of previous OSCC and initial treatment (clinical observation or surgical 
excision: with definitive diagnosis) . The following longitudinal follow-up data were collected 
throughout the duration of clinical follow-up: clinical progression of dysplasia grade or 
malignant transformation (confirmed by biopsy), total number of biopsies/surgical excision 
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carried out, number of visits to the dysplasia clinic, endpoint clinical behaviour of OED/PVL 
lesion: remission/ progression of dysplasia severity/ malignant transformation, length and 
status of follow-up at most recent review: under follow-up, lost to follow-up or discharged.     
Statistical method: Statistical analysis was carried out using the SPSS (Statistical Package 
for the Social Sciences) software, IBM Corporation.  Kaplan-Meier methods were used to 
estimate the percentage of patients who underwent malignant transformation of OED/PVL 
after two and five years, and the log-rank test was used to compare transformation survival 
curves. Cox regression methods were used to investigate the main independent predictors of 
survival.  Hazard ratios (HR) with 95% confidence interval (95% CI) and p values were 
reported (p < 0.05 was considered statistically significant). 
 
Results 
 
145 patients were identified from the database of consented patients. The medical records of 
25 patients were not retrievable, 10 patients did not have a diagnosis OED/PVL and in 12 
patients biopsy of the clinical lesion contained OSCC. Therefore 98 eligible patients (with 
biopsy confirmed OED/PVL) were included for this analysis.  The first clinic appointments for 
these patients were between 11 May 1984 and 16 March 2011.  
The baseline information of all patients included in the study is presented in Table 2.1.  
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 Number of patients (%) 
n=98 
Gender Male 
Female 
48(49) 
50(51) 
Age (at first appointment) <50.0 
50.0-59.9 
>60.0 
26(26.5) 
39(39.8) 
33(33.7) 
Site of OED Floor of mouth (FOM) 
Buccal mucosa 
Lateral tongue 
Others: 
Soft palate 
Mandibular alveolar/gingival 
Maxillary alveolar/ gingival 
Ventral tongue 
Dorsum tongue 
Hard palate 
Tonsillar 
40(40.8) 
19(19.4) 
15(15.3) 
24(24.5) 
7 
6 
2 
5 
1 
1 
1 
Size of OED (largest in 
cases with multiple 
lesions) *  
< 200mm2 
> 200 mm2 
39(40.6) 
57(59.4) 
Diagnosis (first biopsy) Mild dysplasia 
Moderate dysplasia 
Severe dysplasia 
Proliferative verrucous leukoplakia 
Others** 
33(33.7) 
26(26.5) 
19(19.4) 
7(7.1) 
13(13.3) 
Number of lesions Single 
Multiple 
74(75.5) 
24(24.5) 
Clinical appearance Homogenous white 
Others: 
Erythroleukoplakia 
Erosive (red patch) 
Ulcer 
70(71.4) 
28(28.6) 
19 
7 
2 
Smoking history Never or <5 pack years 
5-20 pack years 
>20 pack years 
23(23.5) 
30(30.6) 
45(45.9) 
Alcohol consumption Teetotal or <5 units per week 
5-20 units per week 
>20 units per week 
47(48.0) 
28(28.6) 
23(23.5) 
Previous OSCC Yes 
No 
5(5.1) 
93(94.9) 
 
* not known for 2 patients therefore n=96(100%) for this parameter. The size of OED was 
derived from a combination of photographic recorded dimensions, clinical notes and 
pathology records from resected lesions. 
**includes chronic hyperplastic candidiasis, lichenoid changes and lichen planus which 
subsequently when re-biopsied showed features of OED/PVL 
 
Table 2. 1 Baseline information of 98 patients at initial presentation 
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At the most recent clinical review, the endpoint of OED/PVL lesion were: 26(26.5%) patients 
had malignant transformation, 6(6.1%) had progressed to a more severe grade of dysplasia 
and 66(67.4%) were either stable or had resolved spontaneously.  Excluding the PVL patients 
(based on the published diagnostic criteria(67, 73)), 78 patients had a diagnosis of OED from 
their initial biopsy and within this subgroup, 19 (24.4%) underwent malignant transformation. 
Overall, the median time from malignant transformation from first clinic appointment was 
47.7 months (IQR 16.3-83.9). Three patients underwent malignant transformation from PVL 
with median transformation time of 33.5 months (IQR 24-145). 
Patient factors were analysed with respect to malignant transformation rate of OED/PVL by 
univariate Kaplan-Meier analyses to compare the transformation curves and estimate the 
percentage of patients who had malignant transformation after two and five years (Table 
2.2).  
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   Transformation rate estimate 
 
  Patients 2yr 5yr Log rank test 
 TOTAL 98 12 (4) 23 (5)  
Gender Male 50 8 (5) 18 (8) χ2=0.4 
p=0.50  Female 48 16 (5) 27 (7) 
Age <50 26 4 (4) 16 (9) 
χ2=2.5 
p=0.29 
 50-59 39 14 (7) 20 (8) 
 60+ 33 17 (7) 33 (10) 
Site Floor of Mouth 40 3 (3) 8 (6) 
χ2=13.0 
p=0.005 
 Buccal 19 6 (6) 24 (13) 
 Lateral Tongue 15 29 (12) 53 (16) 
 Other 24 18 (8) 24 (10) 
Size of lesion* <200 mm2 39 7 (5) 13 (7) χ2=3.9 
p=0.05  200+ mm2 57 16 (5) 30 (7) 
Diagnosis  
(first biopsy) 
Mild 33 3 (3) 19 (9) 
χ2=7.7 
p=0.05 
 Moderate 26 0 (-) 17 (11) 
 Severe 19 38 (12) 38 (12) 
 Other 20 18 (10) 24 (11) 
Number of 
lesions 
Multiple 24 18 (8) 26 (11) 
χ2=0.4 
p=0.55 
 Single 74 10 (4) 22 (6) 
Appearance Homogenous 
white 
70 5 (3) 16 (6) 
χ2=8.9 
p=0.003 
 Other 28 29 (10) 41 (11) 
Smoking Never or <5 
pack years 
23 28 (10) 43 (12) 
χ2=15.7 
p<0.001  5-20 pack years 30 7 (5) 29 (11) 
 >20 pack years 45 7 (5) 7 (5) 
Alcohol Teetotal or 
<5units/week 
47 12 (5) 25 (7) 
χ2=0.4 
p=0.81 
 5-20 units per 
week 
28 18 (9) 26 (11) 
 >20 units per 
week 
23 5 (5) 17 (12) 
*NK for 2 
 
Table 2. 2 Two and five-year Kaplan-Meier transformation rates % (Standard Error(SE))   
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The strongest univariate predictors were smoking status, appearance and tumour site, 
followed by severity of dysplasia and size of lesion (Figures 2.1 and 2.2, Table 2.3).  
 
 
Figure 2. 1 Kaplan-Meier curves for malignant transformation rates: smoking history 
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Figure 2. 2 Kaplan-Meier curves for malignant transformation rates: appearance of lesion 
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 Malignant 
transformation (%) 
Progression of 
dysplasia (%) 
Remission (%) 
Smoking history 
Never of <5 pack yrs  
5-20 pack yrs 
>20 pack yrs 
 
12(52.1) 
9(30) 
5(11.1) 
 
1(4) 
2(6.7) 
3(6.7) 
 
10(43.5) 
19(63.3) 
37(82.2) 
Clinical appearance 
Homogenous white 
Others 
 
12(17.1) 
14(50) 
 
5(7.1) 
1(3.6) 
 
53(75.8) 
13(46.4) 
Site of lesion (n=55) 
FOM 
Lateral tongue 
 
6(15) 
9(60) 
 
2(5) 
1(6.7) 
 
32(80) 
5(33.3) 
Dysplasia grade (n=78) 
Mild 
Moderate 
Severe 
 
6(18) 
5(19.2) 
8(42.1) 
 
1(3) 
- 
2(10.5) 
 
26(79) 
21(80.8) 
9(47.4) 
 
Table 2. 3 Number of patients who experienced malignant transformation of clinical 
OED/PVL for selected parameters (n=98 unless specified). 
 
Patient factors (apart from previous history of OSCC) were used in stepwise multivariable Cox 
regression modelling. The first predictor into the regression was smoking status (at p<0.001), 
and then appearance (p=0.03) for its extra independent contribution to the model (extra χ
2=5.0) (Table 2.4).   
 
 
 
 
 
 
 
 
 
36 
 
 
 Hazard ratio (relative risk of 
malignant transformation) 
95% CI of Hazard ratio 
Smoking status:   
   >20 pack years Relative to ‘>20 pack years’  
   5-20 pack years 2.3 
 
0.8 - 6.9 
 
Never or <5 pack years 5.2 
 
1.8 -15.0 
 
Appearance:   
Homogenous white Relative to ‘Homogenous white’  
   Other                       2.4 1.1 – 5.2 
 
Table 2. 4 Final model of independent predictors for the 98 patients using multi-variable 
Cox regression. 
 
Kaplan-Meier estimates for smoking status stratified by appearance were then determined 
(Table 2.5).  
 
   Transformation rate estimate 
  Patients 2yr 5yr Log rank test 
Appearance: Homogenous white 
Smoking Never or 
<5pack yrs 
12 8 (7) 33 (16) 
χ2=6.5 
p=0.03  5-20 pack yrs 19 5 (5) 22 (11) 
 >20 pack yrs 34 4 (4) 4 (4) 
Appearance: Other 
Smoking Never or 
<5pack yrs 
8 58 (17) 58 (17) 
χ2=6.3 
p=0.08  5-20 pack yrs 10 10 (10) 38 (18) 
 >20 pack yrs 8 20 (18) 20 (18) 
 
Table 2. 5 Kaplan-Meier analyses with regard to smoking status and lesion appearance.  
2 and 5-year Kaplan-Meier transformation rates (SE).  
 
When smoking status was excluded, then only appearance was selected in the regression 
modelling, with tumour site borderline for independent entry at p=0.08 in addition to 
appearance. The risk of malignant transformation for the different levels of smoking, 
adjusted for appearance was significant (Chi-squared 12.7, p=0.002), as was that for the 
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different levels of appearance, adjusted for smoking status (Chi-squared 5.7, p=0.02) (Table 
2.5). A chi-squared test comparing the malignant transformation Kaplan-Meier curves of 
severe dysplasia (high-risk) with mild and moderate dysplasia (low-risk) (Figure 2.3) was 
significant (p=0.012) and Cox regression gave a hazard ratio of 3.2 (95% CI 1.0-7.9; p=0.01)).  
 
 
Figure 2. 3 Kaplan-Meier curves for malignant transformation rates: grade/severity of 
dysplasia ('others' excluded) 
 
The clinical intention to treat OED/PVL lesions by the clinician after initial assessment (excise 
vs review) did not influence malignant transformation rate (Table 2.6).  
Data related to the number of incisional biopsies and surgical excisions, number of clinic 
attendances and follow-up duration is shown in Table 2.7. The follow-up status of patients at 
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the time of reporting was: 48(49%) under follow-up, 38(38.8%) lost to follow-up and 
12(12.2%) discharged to follow-up in the primary/secondary care (low-risk lesions).  
 
Groups 
n = 98 
Treatment intention: 
surgical excision – 
n(%) 
Treatment intention: 
clinical surveillance – 
n(%) 
Fisher exact test 
Malignant 
transformers (n=26) 
5 (5) 21 (21) p = 0.534 
Stable and 
progression (n=72) 
10 (10) 62 (64) 
 
Table 2. 6 Comparison of treatment intent for OED which have undergone malignant 
transformation vs. stable OED. 
 
 
 
Group Total number of biopsies 
(and surgical excision) 
Median (IQR) 
Number of clinic 
attendances 
Median (IQR) 
Follow-up period 
(months) 
Median (IQR) 
Malignant 
transformers (n=26) 
4(3.0-6.25) 15(10.75-29) 80.5(35.2-125.6) 
Stable and 
progression (n=72) 
1(1-2) 9(5-18) 41.9(15.0-80.3) 
All patients (n=98) 2(1-3) 12(6-19) 49(19-95) 
 
Table 2. 7 Total number of biopsies (and surgical excision), number of clinic attendances 
and follow-up duration for 98 patients 
 
Discussion 
 
In this study, we discovered a notably high malignant transformation rate of 26.5% amongst 
patients diagnosed with OED offered prolonged follow-up.  Factors such as non-smoking, 
lateral tongue site and non-homogenous appearance were all associated with a malignant 
transformation rate in excess of 40%, although the former two were inter-dependent factors.  
Non-smokers were 5.2 times more likely to undergo malignant transformation compared to 
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heavy smokers.  Malignant transformation occurred after a median of 4 years following 
diagnosis of dysplasia. 
The overall malignant transformation rate in this study was 26.5% compared with 7-27%, for 
OED, reported in several hospital-based cohorts(5, 59, 66); thus, falling at the higher end of 
the spectrum. One possible reason for this could be recruitment bias due to the tertiary 
nature of the Regional Dysplasia Clinic, although this setting is common to most other 
studies. It is, of course, not a population-based cohort, therefore the characteristics and 
outcomes of those lesions not referred to the clinic remains unknown.  Most publications in 
the literature report oral leukoplakia, a clinical entity(9, 10, 16, 74) but the inclusion criteria 
of biopsy confirmed OED in this study will also likely contribute to the high rates seen. The 
advantages of following a tight inclusion protocol with prolonged follow-up seen in this series 
are self-evident. PVL was included within the analysed group as clinically the appearance may 
be similar, and the life-long implications and risks of malignant transformation may be 
considered broadly comparable(67, 75, 76).  
The significant high-risk nature (5.2 x) of lesions in non-smokers is particularly noteworthy 
and was also reflected in the consistency of trend, with the intermediate group (5-20 pack 
years) having intermediate (2.3 x) risk more likely to undergo transformation than heavy 
smokers. When the effect of smoking on gender with relation to malignant transformation 
was assessed, male non-smokers had a transformation rate of 57% (4/7) when compared 
with female non-smokers (50%; 8/16). This contrasted with findings of previous authors, who 
reported OED with more aggressive behaviour only in female non-smokers(9, 10). It has to be 
clarified that these observations do not imply that smoking is protective of malignant 
transformation in OED, but in the presence of environmental triggers for the process of 
carcinogenesis, elimination of these triggers such as tobacco use has been known to result in 
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resolution of OED especially in the floor of mouth subsite(77). In contrast, the finding of OED 
in non-smokers (and/or drinkers) would suggest an endogenous aetiology. The disease 
pattern in ‘endogenous’ OED has been seen more in the lateral tongue subsite and has been 
reported in several cohorts to have a higher risk of malignant transformation than those seen 
in smokers have a higher proportion of OED located in the floor of mouth or palate when 
compared to non-smokers(61, 62, 78, 79). There is emerging evidence to suggest that It is 
likely that these underlying “endogenous” factors, in the absence of tobacco smoking, act 
irrespective of gender(61).  
Non-homogenous lesions were 2.4 times more likely to undergo malignant transformation, 
consistent with several previous reports(9, 10, 21, 65), one of which found this to be the only 
factor predictive of malignant transformation(59). The non-homogenous appearance of the 
lesion, amongst other patient factors, has raised clinical suspicion and resulted in the 
prescription of a more aggressive approach to treatment by surgical excision (Table 2.6). 
Although method of treatment did not influence malignant transformation rates, it was felt 
this would likely be strongly influenced by prescription bias so have not felt further analysis 
particularly valuable.   
In terms of histological grade, high grade OED (42.1% malignant transformation, 8/19) were 
3.2 times more likely to undergo malignant transformation compared with low grade lesions. 
The validity of grading of OED has been questioned due to the possibility of intra and inter-
observer variability(59) and therefore a binary system has been suggested to reduce this 
effect and enhance clinical relevance(58). In our study, the pathology specimens were 
reported by two oral pathologists (Julia Woolgar and Asterios Triantafyllou), giving 
consistency in grading. 
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The lateral tongue and floor of mouth have both previously been associated with an 
increased risk of malignant transformation(5, 18). Recent evidence suggests that the 
characteristics of OED in smokers vs. non-smokers differ especially in relation to the site of 
OED as shown in this cohort and their respective transformation rates, higher in non-smokers 
and lateral tongue(61). Whilst the site of OED had significant impact on the risk of malignant 
transformation, the findings reported, and emerging evidence supports the influence of 
smoking status on OED behaviour in relation to its location.  In our study, lesions on the 
lateral tongue had the highest propensity for malignant transformation (60%; 9/15) whilst 
the commonest site with OED/PVL was the FOM, making up 40.8% (40/98) of lesions, with 
malignant transformation seen in only 6 (15% of FOM lesion) patients. This unexpectedly 
large difference highlights the need for close supervision in lateral tongue lesions (Figures 2.4 
and 2.5).  
 
 
Figure 2. 4 Leukoplakia lateral border of tongue in lifelong non-smoker, histology shows 
severe dysplasia: high risk of malignant transformation (approx. 40-50%). 
 
42 
 
 
Figure 2. 5 Floor of mouth lesion in heavy smoker with moderate risk (approx. 10-15%) of 
malignant transformation. 
 
The size of the lesion, although not independently predictive of malignant transformation, 
was statistically significant when the transformation rates were compared, and larger lesions 
(>200mm2) appear to have a higher propensity for malignant transformation supported by 
findings of earlier reports(21, 65). 
The median time to malignant transformation of 47.7 months in our cohort supports the 
need for long-term clinical follow-up of OED/PVL, with the longest case taking 256.5 months 
for malignant transformation, not dissimilar to results of a recent meta-analysis(20).  . In the 
indication for intervention, there could potentially have been some prescription and selection 
bias, and this could vary between clinicians. The sample size, while comparable to reported 
cohorts in the literature, is still relatively small and the difficulties encountered with statistical 
power in such situations apply here as well. Furthermore, when logistic regression was 
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applied the box size becomes even smaller, thus data has to be interpreted within this 
context. 
The clinical determinants of malignant transformation reported here will guide the advice 
given and interventions prescribed to patients.  The observations reported also highlight the 
need to understand the differing risk, and perhaps differing mechanism of carcinogenic 
route, between smoking-associated and non-smoking associated OED. It is also notable that 
the prolonged follow-up and multiple interventions in a multi-disciplinary clinic described 
above carry significant financial costs. In the face of apparently high risk lesions these costs 
appear to be justified. The outcomes of intervention in patient who underwent malignant 
transformation would inform the viability of the approach adopted. Safe de-escalation of care 
for those with lower risk, for example, to review in primary care may also be possible. 
Stratification of patients will likely depend on clinical and histological features, but 
additionally with the development of predictive biomarkers reflecting the known genetic(80, 
81) and epigenetic(82, 83) determinants of malignant progression. 
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Chapter 3 Outcomes of oral squamous cell carcinoma arising from 
oral epithelial dysplasia: the rationale for monitoring of oral 
premalignant lesions in a multidisciplinary clinic 
 
Introduction 
 
Prompt intervention in the management of early stage oral squamous cell carcinoma (OSCC) 
remains the most reliable means of achieving the best possible survival and functional 
outcomes(1, 84-86).  Therefore, the infrastructure of service provision should facilitate the 
process of early detection and diagnosis of OSCC followed by a seamless care pathway, 
where there is minimal delay to definitive surgery. Recent reviews(87-90) have suggested 
that opportunistic screening in the high-risk group of patients within the primary health care 
setting by general dental practitioners may be feasible and cost-effective and there is 
emerging evidence that a population based approach, targeting high-risk groups can improve 
early detection rates of oral cancer(91). Extrapolation of these suggestions would support 
targeted screening of patients with potentially malignant oral lesions (mostly oral epithelial 
dysplasia (OED)) within a secondary or tertiary multidisciplinary clinic (with representatives 
from oral and maxillofacial surgery, oral medicine and oral pathology). The multidisciplinary 
team approach improves patient care by concentration of expertise, which would be 
enhanced by experience in the management of complex cases, leading to improved patient 
care.  This environment also creates an excellent training opportunity and facilitates patient 
recruitment into clinical studies which could inform future practice and identify areas for 
further research(83). It has been alluded to the fact that this group of patients reported in 
Chapter 2 justified long term follow-up to manage a presumably increased risk of second 
primary tumours and further OED. The aim of this chapter is to describe the clinical 
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management and outcomes of OSCC arising from monitored OED in a dedicated 
multidisciplinary clinic. 
Patients and methods 
 
Inclusion criteria 
The inclusion and exclusion criteria of the OED cohort has been described in the previous 
chapter. Briefly, this included histologically diagnosed OED in 91 patients who were recruited 
prospectively into a clinical and molecular biomarker study since September 1999 (ethical 
approval by Sefton REC; Reference number: EC 47.01), with first clinic appointment dates 
between May 1984-March 2011 (median follow up of 48 months (IQR 18-96)).  The data 
presented here includes all those patients within the cohort who underwent malignant 
transformation. 
Data collection 
The following data fields were extracted from the main database: demographic details (age, 
gender), smoking and alcohol history, site and initial grade of OED, cTNM on presentation to 
the Head and Neck Multidisciplinary Team, extent and modality of surgical intervention, time 
from first appointment in the Liverpool Regional OED Clinic to malignant transformation, and 
local recurrence of excised OSCC (defined as recurrence within same subsite within 2 years). 
Additional features noted include the development of metachronous OED in a separate oral 
cavity subsite, follow-up duration and clinical status at the most recent update of database.  
Results 
Twenty-three (25%) patients underwent malignant transformation over the period of this 
study.  The median age at transformation was 57.5 years (IQR 50.1-68.8), median time to 
malignant transformation from first clinic appointment was 40.3 months (IQR 12.1-67.2). The 
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median duration of follow-up following cancer diagnosis was 24 months (IQR 11-58). Four 
patients had surgical excision of clinically unsuspected OSCC following planned interval 
biopsies. In the remaining 19, malignant transformation was detected following biopsy 
triggered by clinical suspicion (i.e. unplanned biopsies).  All transforming patients were 
presented to the Head and Neck Multidisciplinary Team with Stage 1 OSCC (cT1N0M0). 
Twenty-one patients underwent wide local excision of their OSCC (including one localised 
maxillary alveolectomy and one mandibular rim resection, for marginal clearance); and 2 
required tumour resection, selective neck dissection and reconstruction with microvascular 
free tissue transfer (fasciocutaneous radial forearm and vascularised iliac crest). All 23 
patients were confirmed as pT1N0M0 following surgical excision. One required adjuvant 
radiotherapy for close deep margin. Three (13%) patients developed local recurrence, one 
(4%) contralateral regional recurrence and one (4%) distant metastasis (pulmonary).  Five 
patients (22%) developed new primary OSCC and another five had histological diagnosis of 
(22%) further OED on subsequent biopsy. All local recurrences and second primary tumours 
were surgically excised and the patient who had regional recurrence underwent extended 
selective neck dissection and adjuvant radiotherapy. The disease specific survival was 100% 
and overall survival 96% (22/23) when clinical outcome data was updated at the endpoint of 
study. The demographics and treatment outcomes of these patients have been summarised 
in Table 3.1.  
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Table 3. 1 Summary of demographic and treatment outcomes of 23 patients in whom OED underwent malignant transformation (OSCC) MT - malignant 
transformation, FOM - floor of mouth, WLE - wide local excision (laser or cold steel), NDFFR - tumour resected with neck dissection and microvascular free tissue 
transfer reconstruction; D=discharged, UF=under follow-up, LF=lost to follow-up 
ID Age  Sex Smoking 
Alcohol 
units/week Site 
Index 
Diagnosis 
(grade of 
dysplasia) 
Time to 
malignant 
trans from 
1st clinic 
appt(mths) Surgery 
Local 
recurrent 
SCC 
Further 
new 
SCC 
Further 
dysplasia 
No of 
further 
excision 
Total 
follow-up 
in OED 
clinic 
(mths) 
Clinical 
status 
1 85.2 M Never  Teetotaller Lat tongue severe  6.67 WLE Y  N N 1 94.8 UF 
22 49.2 F <5 pack years 5-20 units Lat tongue severe  65.22 WLE Y  N N 1 111.6 UF 
21 57.5 M 5-20 pack years <5 Lat tongue moderate  83.65 WLE N Y N 1 147.6 UF 
17 69.3 F Never  Teetotaller Lat tongue severe  14.78 WLE N Y Y 1 36 UF 
8 46.1 F Never  <5 Lat tongue mild  36.80 WLE N N Y 1 58.8 UF 
23 37.5 M 5-20 pack years 21-40 Lat tongue mild  53.55 WLE N N Y 0 115.2 UF 
4 44.7 F 5-20 pack years <5 Lat tongue severe  78.59 WLE N N N 0 82.8 UF 
6 54.7 F Never  5-20 units Lat tongue severe  13.90 WLE N N N 0 13.2 UF 
12 52.0 M Never  5-20 units Lat tongue moderate  4.04 WLE N N N 0 32.4 UF 
13 65.1 F Never  Teetotaller Lat tongue moderate  82.96 WLE N N N 0 121.2 LF 
7 45.2 F 5-20 pack years <5 
Ventral 
tongue mild  40.34 WLE N Y Y 1 24 
UF 
11 68.8 F 5-20 pack years Teetotaller 
Ventral 
tongue moderate  42.64 WLE N N N 0 52.8 
UF 
15 72.6 F 5-20 pack years 5-20 units Buccal mild  35.94 WLE Y  N N 1 118.8 LF 
5 44.6 F >20 pack years Teetotaller Buccal moderate  69.19 
Localised 
alveolectomy N Y N 0 256.8 
UF 
20 58.0 F 5-20 pack years <5 Buccal moderate  49.12 WLE N Y Y 2 145.2 UF 
3 51.8 M Never  <5 Buccal moderate  4.30 NDFFR N N N 0 196.8 UF 
2 87.2 F Never  Teetotaller Retromolar severe  4.86 NDFFR N N N 0 25.2 UF 
10 68.8 M 5-20 pack years 21-40 FOM severe  2.10 WLE N N N 0 21.6 UF 
9 68.7 F >20 pack years 21-40 FOM moderate  63.34 WLE N N N 0 78 UF 
14 53.1 M >20 pack years 5-20 units FOM mild  90.61 WLE N N N 0 116.4 LF 
16 72.9 M Never  <5 FOM moderate  10.38 Rim mandible N N N 0 57.6 UF 
18 60.9 M 5-20 pack years >40 FOM severe  90.18 WLE N N N 0 145.2 D 
19 50.9 F >20 pack years 5-20 units Soft palate severe  16.43 WLE N N N 0 21.6 UF 
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Discussion  
 
The treatment outcomes of early OSCC which had arisen from OED in this cohort appeared to 
have excellent regional recurrence and disease specific survival outcomes when compared 
with previous OSCC cohorts(1, 86, 92, 93); reported as regional recurrence 10-31% and 
disease specific survival 46-86%. The local recurrence rate was marginally higher than 
previously reported, 8-12%(1, 86, 92, 93) and the second primary tumour rate was within the 
higher end of reported figures, 7-32%(1, 94). These excellent outcomes were achieved 
following relatively minor treatment: surgical intervention consisted of localised treatment to 
the primary tumour sites in 87% (20/23) of patients (including treatment for local and 
regional recurrences). It is understood that this cohort is the first report of treatment 
outcomes of OSCC which had arisen from OED monitored in a dedicated oral dysplasia 
multidisciplinary team clinic. 
In acknowledging the limitations of this data, it has been recognised that an element of bias 
towards high risk OED cases were included within the research cohort.  The overall number 
of OSCC arising from OED within this cohort is modest.  It was assumed in the analysis that all 
the early stage OSCC would have progressed to larger tumours if left untreated, and this is 
perhaps a matter for debate as occasional tumours may regress spontaneously. 
 In order to conclusively prove the benefit of specialist surveillance by a multidisciplinary 
team, comparison with a control group of, for example, OSCC arising from OED but not 
subject to surveillance, would be required, however this data is not available. Anecdotally, 
there have been cases of T2, T3 and T4 OSCC at presentation to the MDT despite previous 
histological diagnoses of OED not subject to formal surveillance, however there is no reliable 
mean of capturing this data. Patient satisfaction in this cohort was not formally measured, 
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however, there was a low non-attendance rate. Those patients who underwent malignant 
transformation and were counselled by members of the multidisciplinary team received their 
treatment through a seamless care pathway with minimal delay.  
In order to give context to the outcomes of this group of 23 patients, data from 489 OSCC 
patients treated by primary surgery 1992-2002(1) is summarised and contrasted in Table 3.2 
(patients from the same geographical catchment area).   
 
 
 
 Early OSCC from OED 
1984-2012 
(23 patients) 
% (n) 
Liverpool OSCC cohort 
1992-2002  
(489 patients) 
%(n) 
Treatment details:   
Surgery to primary site only 91(21) 18(89) 
Neck dissection 9(2) 82(400) 
Free flap reconstruction 9(2) 76(373) 
Primary surgery & adjuvant radiotherapy 4(1) 40(194) 
Disease related outcomes:   
Local recurrence 14(3) 10(50) 
Regional*/loco-regional** recurrence 4*(1) 21**(103) 
New primary OSCC 22(5) 7(35) 
Freedom from loco-regional recurrence  83(19) 76(373)a 
Disease specific survival 100(23) 74(362)a 
  
a. Data based on Kaplan Meier curves estimate at 5 years 
 
Table 3. 2  Data from early OSCC from OED cohort from this study and the Liverpool 
1992-2002 OSCC cohort(1): treatment details and disease related outcomes. 
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Although direct comparison between this cohort and other OSCC cohorts would not be 
entirely reliable (as it is all but certain that all the previously reported cohorts would have 
contained patients with precursor OED), the contrasting outcomes offers some perspective. 
The relatively minor nature of surgical intervention and excellent outcomes in the 
management of OED derived OSCC (Figures 3.1 & 3.2) are apparent.   
 
 
  
 
 
Figure 3. 1 Left lateral tongue microinvasive SCC: pre-treatment (left) and complete 
healing following excision with laser (right) 
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Figure 3. 2 Right lateral tongue severe dysplasia (top left) underwent malignant 
transformation to microinvasive SCC (top right) with complete healing following laser excision 
(bottom centre) 
 
This would indicate rather less patient morbidity, fewer serious complications and a greatly 
reduced burden of treatment to patients and health service overall(95, 96). The higher local 
recurrence and second primary tumour rate reported is likely to reflect the high-risk nature 
of patients followed up in the Regional Oral Dysplasia clinic, in whom the oral mucosa is 
unstable (field change) (Figure 3.3). 
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Kaplan-Meier estimates of 12-month event free survival (with standard error): 80% (SE 9%) 
Kaplan-Meier estimates of 24-month event free survival (with standard error): 61% (SE 12%) 
Kaplan-Meier estimates of 60-month event free survival (with standard error): 24% (SE 14%) 
 
Figure 3. 3 Time from date of malignant transformation to first occurrence date of any of 
second event (local recurrent SCC, new primary, SCC, further dysplasia, death) or in the 
absence of an event to the date lost to follow-up. 
 
As previously suggested(97), it is postulated that there are possible endogenous factors 
within some of the patient population which could account for this behaviour, in addition to 
the most common environmental factors such as tobacco and alcohol exposure. The 
additional cost of long-term regular follow-up of OED in a multidisciplinary setting needs to 
be weighed against the costs of surveillance and might make a health economic approach 
worthwhile.  The data presented demonstrates a pivotal role for multidisciplinary input with 
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representation from the Head and Neck Multidisciplinary team, in this case facilitated by oral 
and maxillofacial surgery in the oral dysplasia clinic, acting as intermediary between 
surveillance in the oral dysplasia clinic and the MDT. 
The outcomes reported in this chapter appear to favour long term clinical monitoring of OED 
within a multidisciplinary clinic. The advantages of long-term review for OED patients are 
clear, necessitated by the median interval to malignant transformation >3 years and high 
local recurrence and second primary tumour rates (76% at 5 years). Better predictive models 
for transformation would aid inclusion to a surveillance programme and tailoring of that 
programme to the patients’ individual risks. As in other areas of personalised medicine, these 
models will likely include histopathology, clinical and demographic characteristics as well as 
molecular biomarkers. 
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Chapter 4 Surgical management of oral dysplasia 
 
Introduction 
Surgical excision has been the preferred modality of treatment in the management of 
OED(70), despite the lack of evidence from randomised controlled trials(16). Even with a 
policy of surgical excision,  recurrence rates of up to 35% have been reported(18), however, 
it has been suggested that monitored lesions demonstrate a higher rate of malignant 
transformation compared with those that are excised(20, 71).  Although molecular 
biomarkers such as DNA aneuploidy(98), loss of heterozygosity(99) or DNA methylation(83) 
of key tumour suppressor genes are actively researched and demonstrate correlation to risk 
of malignant transformation, these have yet to translate to mainstream clinical practice. The 
decision to offer surveillance or surgical excision is therefore made on clinical grounds using 
the factors described(97), and histological grading. 
Surveillance of OED results in a number of newly diagnosed OSCC. Therefore, the 
infrastructure of service provision should facilitate the process of early detection and 
diagnosis of OSCC followed by a seamless care pathway, where there is minimal delay to 
definitive surgery. Prompt intervention in the management of early stage OSCC remains the 
most reliable means of achieving the best possible survival and functional outcomes(1, 84-
86). It is helpful to manage such lesions in dedicated tertiary multidisciplinary clinic (with 
representatives from oral and maxillofacial surgery, oral medicine and oral pathology).  There 
has been some local evidence to suggest that such arrangements allow cases that (inevitably) 
transform to frank malignancy to be managed rapidly and with excellent results(100). These 
cases can usually be treated with single modality and with superior recurrence and survival 
outcomes compared to OSCC arising from other referral pathways(1, 100) (Table 3.2). 
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CO2 Laser surgery for oral lesions with malignant potential 
CO2 laser is the most commonly used laser in the surgical management oral cavity soft tissue 
excision or ablation(101-109). Alternative laser systems include NdYAG or diode laser(71). It 
has been proven to be safe and effective as its coherent beam is almost completely absorbed 
by intracellular water. When used as a precise cutting instrument in the oral cavity, 1mm 
diameter focus beam at 5-7W super-pulsed continuous setting, it also achieves haemostasis 
by photo thermocoagulation allowing clear visibility to the surgical site and sealing off nerve 
endings resulting in less pain post-surgery. It can also be used to achieve ablation, 3mm 
diameter defocused beam at 4-6W super-pulsed continuous setting. A micro-manipulator can 
be used for improved accuracy in posterior lesions but in practice most oral cavity laser 
surgery is carried out by a free handpiece.  Utility of an operating microscope could enhance 
tissue preservation in the absence of a malignant diagnosis, however the set-up and 
procedure could be more time consuming.  
Peripheral excision margins of 3-5mm depending on the size and severity of dysplasia 
grade(22), of the lesion would seem appropriate with depth of excision down to the 
connective tissue layer (adipose/muscular tissue depending on site) (Figures 4.1 and 4.2).  
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Figure 4. 1 Non-homogenous premalignant lesion on the lateral tongue in a non-smoker 
(high risk lesion). 
 
 
 
Figure 4. 2 Lateral tongue wound left to heal by secondary intention following laser 
excision of mucosal layer down to intrinsic muscles of tongue with excellent haemostasis. 
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It should be borne in mind that a significant proportion of laser resections for dysplasia 
harbour OSCC on the final histological report(101). Demarcation of the oral dysplastic lesion 
and its margins is sometimes enhanced with the use of toluidine blue(110) or Lugol's Iodine 
solution(111), although the objective benefit of either has yet to be demonstrated in high 
quality studies, their role in identification of high risk lesions, selecting biopsy sites and 
helping to ensure clear margins is potentially promising (112-114).  Laser surgery offers the 
reported advantage of; haemorrhage control, improved visibility and shortening of operative 
time, along with decreased post-operative pain and swelling, minimal scarring and good post-
operative tissue mobility(115).  Laser excision is usually preferred over ablation as it allows 
definitive diagnosis through histopathological tissue examination, which aids clinical 
management, bio banking, research and documentation for clinical governance or medico-
legal purposes.     
Healing is primarily by secondary intention with complete re-epithelialisation after 4-6 
weeks(116) (Figures 4.3 and 4.4).   
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Figure 4. 3 Preoperative appearance of homogenous right buccal mucosal lesion (severe 
dysplasia). 
 
 
Figure 4. 4 Three-year follow-up appearance of well healed scar following excision. 
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The buccal mucosa has the tendency for more adverse scarring and fibrosis which can cause 
trismus. Therefore, for more extensive buccal lesions (>2cm diameter), it is advocated that 
reconstruction should be considered with one of the following options: the buccal fat pad, 
split thickness skin graft 'immobilised' by a bolster dressing or free tissue transfer.  
In the anterior floor of mouth, which is a very common site for OED, management the 
submandibular duct(s) need to be carefully considered.  In the event that the submandibular 
duct becomes stenosed or obstructed after excision, the resultant obstructive sialadenopathy 
causes patient discomfort(117) and, critically, may mask or simulate cervical metastasis.  The 
submandibular duct(s) should be identified by careful dissection during laser excision and 
posteriorly repositioned (Figures 4.5-4.9). 
 
 
 
Figure 4. 5 Erythroleukoplakia anterior floor of mouth in a smoker (high risk lesion). 
 
60 
 
 
 
Figure 4. 6 Appearance of lesion following staining with Lugol's Iodine solution: area of 
pallor  indicates mucosal dysplastic change.  
 
 
 
 
 
 
 
 
 
61 
 
 
 
Figure 4. 7 Peripheral excision margin delineated with CO2 laser 5mm from area 
highlighted by  Lugol's Iodine staining (1mm beam spot, 6W super-pulsed continuous setting): 
precise cut edge with excellent haemostasis allowing clear visibility. 
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Figure 4. 8 The submandibular ducts were carefully dissected out and divided to achieve 
safe excision margins. The proximal cut ends were then secured with 6/0 monofilament 
sutures to prevent retraction and aid localisation. 
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Figure 4. 9 The submandibular ducts positioned posteriorly through a stab incision in the 
floor of mouth mucosa with a No. 11 scalpel blade and inset in place with 6/0 monofilament 
sutures.  The wound was left to heal by secondary intention following CO2 laser excision. 
 
This is a technically demanding procedure but it effective in preservation of asymptomatic 
submandibular salivary gland function. 
 The excision of small (or anterior) oral premalignant lesions can usually be done as a day 
surgery procedure under local or general anaesthesia. Where possible nerve blocks should be 
utilised in preference to local infiltration as the latter could mask bleeding blood vessels due 
to vasoconstriction by epinephrine. Excision of larger (or posterior) lesions is usually more 
successful using general anaesthesia to allow optimal control of the surgical site and for 
patient comfort, and it may be necessary for patients to stay for a period of observation due 
to increased risk of bleeding and need to resume adequate oral alimentation.   
Complications are occasionally seen after laser excision of OED.  If infection occurs in the 
granulating lesion, there may be bleeding which although usually minor may on occasion 
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require readmission and operative haemostasis. Following excision of larger lesions, there is 
 frequently a period of post-operative pain which can last for up to 6 weeks.  Furthermore, 
some lesions, particularly in the tongue can be subject to “over-granulation” resulting in an 
exophytic polypoid mass as the site of laser excision (Figure 4.10). Although these will often 
settle with conservative management, there is sometimes a diagnostic uncertainty regarding 
presence of malignancy in such lesions so re-excision is occasionally mandated. 
 
 
 
 
Figure 4. 10 Left ventral tongue polypoidal mass ("over granulation") can sometimes occur 
during healing following laser excision. 
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Aims and objectives 
 
The literature was reviewed for publications which have reported on the utility of 
interventional laser surgery in the management of oral lesions with malignant potential 
(OLMP). Treatment outcomes such as recurrence of OLMP and malignant transformation 
were the main endpoints assessed. These outcomes were compared between patients who 
were treated by laser excision, laser ablation and cohorts treated by a combination of laser 
excision and/or ablation in the management of oral dysplasia. The main objective of this 
review was to ascertain if there was any difference in recurrence and malignant 
transformation rates between the different techniques of laser surgery in the management 
of OLMP. 
Results 
The studies identified from the literature with clear reported outcomes of recurrence 
following laser treatment of OLMP (which included oral dysplasia, leukoplakia, erythroplakia 
and proliferative verrucous leukoplakia) and malignant transformation rates in their 
respective cohorts have been summarised in Table 4.1. The average recurrence rates of 
OLMP for the three groups of laser interventional surgery (based on pooled data from Table 
4.1) were: laser ablation 52.5%, laser excision 11.6% and laser excision and/or ablation 20%. 
The reported rates of malignant transformation were 0-13%.  The finding of an incidental oral 
squamous cell carcinoma in excised OLMP was seen in up to 12% of patients (118). 
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Surgical technique Author (year) Number of patients 
(number of lesions) 
Mean follow-up 
(range) – months 
Recurrence 
rate (%) 
Transformation 
rate (%) 
Laser ablation Flynn(103) (1988) 14 29 (12-41) 8/14 (57) 1/14 (7) 
Chandu(105) (2005) 39 (69) 42 (2-102) 33/69 (48) 5/39 (13) 
Laser excision Chiesa(101) (1986) 54 24 2/54 (2) 0 
Chu(102) (1988) 28 65 (36-114) 5/28(18) 3 (11) 
Roodenburg(119) 
(1991) 
70 (103) 64 (6-144) 10/103 (10) 0 
Van der Hem(109) 
(2005) 
200 (282) 52 (1-219) 28/282 (10) 3/200 (1) 
Yang(116) (2011) 114 41 (21-109) 20/114 (18) 13/114 (11) 
Laser excision and/or 
ablation 
Frame(120) (1984) (44) 10 (4-24) 6/44 (14) 0 
Thomson(108) (2002) 55 18 (1-44) 12/55 (22) 4 (7) 
Jerjes(106) (2012) 77 (123) 77 15/77 (20) 8/77 (10) 
Del Corso(121) (2015) 77 60 (+ 32) 22 (29) 3 (4) 
Thomson(118) (2017) 590 (773) 7.3 (0-19) * 87/590 (15) 28/590 (5) 
 
 
Table 4. 1  Summary of treatment outcomes of oral premalignant lesions with CO2 laser (* follow-up reported in years)
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Discussion 
 
The main finding from the review of the literature would suggest that in terms of recurrence 
of OLMP laser excision appeared to have a lower rate of recurrence when compared to laser 
ablation. The combined techniques of laser excision and/or ablation resulted in recurrence 
rates better than laser ablation alone but inferior to laser excision. One possible explanation 
for this reported difference could be related to the fact that laser excision requires removal 
of more tissue depth when compared to laser ablation hence allowing more complete 
excision of OLMP. Furthermore, the technique of laser ablation relies on the systematic 
coverage of the area occupied by the OLMP with a defocused laser and treatment outcomes 
would be more sensitive to variability between operators and/or ablation techniques utilised. 
Perhaps of more clinical importance is the finding of an incidental oral cancer in excised 
OLMP (118). Laser excision has in these cases contributed to the early detection of oral 
cancer which might not have been possible in ablative techniques. Therefore, it could be 
argued that from a patient safety and medicolegal perspective, laser excision would be the 
preferred approach over laser ablation. The lower recurrence rates in CO2 laser excision 
when compared to NdYAG laser ablation has been observed in a recent case series, and the 
malignant transformation rate in the reported cohort was higher in the laser ablation group 
of patients(121). Due to the heterogeneity of pathology in the reported studies (Table 4.1), 
statistical comparison between these groups for recurrence and malignant transformation 
rates of a specific histological diagnosis e.g. oral dysplasia, would be difficult and ideally 
require access to original data for a metanalysis. This was not explored or reported in a 
recently published systematic review on the treatment of oral leukoplakia with CO2 
laser(122). Recurrence rates of up to 100% were reported when lesions were excised with a 
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clearance margin of less than 2mm; this figure fell to 10% when lesions were excised with a 
margin of greater than or equal to 3mm(22).  As alluded to earlier, there is potentially a role 
for utility of visual adjuncts in the surgical management of oral dysplasia (or OLMP) as the 
pathology is confined to the epithelial layer and when compared to cancer resections, the 
concern with deep marginal clearance becomes less of an issue. A multi-centre, randomised 
controlled trial has completed recruitment, including 419 patients with oral or oropharyngeal 
cancer, with the aim of assessing the effectiveness of Lugol’s iodine in helping to achieve 
clear mucosal margins(123) . Patients will be followed up for a minimum of 2 years to assess 
the impact of the presence of dysplasia at margins on recurrence, the publication of 
outcomes from this trial is awaited. Based on the evidence reviewed, it would therefore 
suggest that laser excision of oral dysplasia/OLMP would be preferred over ablative 
procedures and potential exists for utility of a cost-effective visual adjunct which would be 
easy to use and is widely available. 
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Chapter 5 The Liverpool Multidisciplinary Approach to the 
Management of Oral Epithelial Dysplasia 
 
Introduction 
 
Oral epithelial dysplasia (OED) together with lichenoid lesions and other conditions such as 
submucous fibrosis, are potentially malignant oral mucosal diseases (PMD).  The significance 
of OED lies in its association with malignant transformation into oral squamous cell 
carcinoma (OSCC)(55, 97).  OED presents histologically as a spectrum of epithelial changes, 
rather than distinct categories.  The WHO (2005 and 2017) system grades it as mild, 
moderate, severe and carcinoma-in-situ(2, 124).  There are other classifications for scoring 
OED, however it is recognized that one limitation of using histological criteria is the 
subjectivity of the WHO grading system.(124-126) 
The major challenge facing the clinician, when a patient is diagnosed as having OED, is 
deciding on their optimal management strategy.  The two pivotal questions, for which there 
are currently no clear-cut answers are: what is the likelihood of an oral lesion with OED 
undergoing malignant transformation to OSCC, and what intervention(s) can mitigate against 
this?  A supplemental question relates to the follow-up of the patient – what is an 
appropriate surveillance programme and how best can this be delivered? 
The first part of this chapter discusses the challenges associated with managing patients with 
OED, including initial diagnosis, the significance of epidemiological, clinical and histological 
factors, management strategies and their efficacy in patients with OED. It is widely 
recognised that there is currently a lack of high-quality evidence, from randomised control 
trials, regarding malignant transformation of OED to formulate evidence-based guidelines.  
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However, clinicians have a duty of care to patients and their relatives/carers to offer advice 
and management, based on the best available evidence.   
 
The second part of this chapter outlines a multidisciplinary approach to the management of 
patients with OED, in the form of an algorithm.  The algorithm is based on best available 
evidence, albeit inconclusive, and the experience of a multidisciplinary, tertiary clinic based in 
the Oral Medicine Unit at Liverpool University Dental Hospital; established to manage high-
risk OED.   
 
The challenges associated with the management of oral epithelial 
dysplasia 
 
The Diagnosis of Oral Epithelial Dysplasia 
 
Despite several studies into alternative methods(3, 112, 127, 128), routine histopathological 
examination remains the gold standard for diagnosis of OED.  It is acknowledged that there 
would be some variability between pathologists in their interpretation of the architectural 
and cellular changes(127).  The use of less invasive, diagnostic measures as adjuncts or 
alternatives to histopathology, such as the use of Lugol’s iodine, toluidine blue, bio-optical 
imaging and cytological specimens have been researched(112, 123, 128-131), but require 
validation.  To date, none of these methods can reliably replace histopathology.  Concerns 
have been raised about the reliability of histopathological examination of incisional biopsy 
specimens, especially in larger lesions as the sample may not be representative of the lesion, 
and these have been comprehensively reviewed elsewhere in the literature(126).  A negative 
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biopsy result may not completely exclude carcinoma or its potential, up to 10% of excised 
oral leukoplakia may contain previously undetected malignant or dysplastic tissue(101).  
Apparently normal mucosa, contralateral to mucosa with confirmed OSCC or OED has also 
been found to harbour dysplastic tissue: in a study of 26 patients with unilateral OSCC or 
OED, 9 (35%) of ‘mirror-image’ biopsies found evidence of dysplasia or microinvasive 
carcinoma(132). 
 
Epidemiological, Clinical & Histological Factors as Predictors of Malignant 
Transformation in Oral Epithelial Dysplasia 
 
The malignant transformation rate of OED has been reported as occurring in 6.6 – 36.4% of 
cases (5, 9, 20, 59, 60, 97, 133, 134) a systematic review and meta-analysis indicated a rate of 
12.1%(20).  An average ‘time to transformation’ has been reported of 0.5 – 17 years (9, 60, 
97, 100).  Mild dysplasia has been reported as showing less than 5% malignant 
transformation, with moderate and severe dysplasia having rates of 3-15% and 7-50% 
respectively(18, 133).  
The findings from Chapter 2 showed 22% of patients undergoing malignant transformation 
within five years, with significant predictive factors being: non-smoking status, site, non-
homogenous appearance and size (>200mm2) of lesion (Table 5.1).   
 
 
 
 
 
72 
 
 
 
 
 
 
 
 
 
Table 5. 1 High Risk, Predictive Features for Malignant Transformation in the Liverpool 
Cohort(97) 
 
Gender, age, number of lesions and alcohol history did not predict for malignant 
transformation (97). The role of predictive biomarkers for malignant transformation in OED 
has yet to be established in clinical practice.  Several studies have identified predictive 
molecular biomarkers that may yet translate into clinical tools (62, 83, 135-137). 
 
The Management of Oral Epithelial Dysplasia 
 
No consensus exists on the appropriate management of dysplastic lesions of the oral mucosa.  
Surgical excision is frequently carried out and there is some evidence to suggest that this 
reduces the risk of malignant transformation when compared with active surveillance(71, 
138).  A systematic review of OED, involving 992 patients, showed that lesions that were not 
excised showed significantly higher transformation rates than those that were excised(20). 
Smoking more than 20 cigarettes per day and consuming more than 100g of alcohol a day 
increases the risk of developing OED; this risk declines, following smoking cessation, back to 
that of the general population after 10-15 years(139).  Smoking cessation can result in the 
disappearance of a substantial number of oral leukoplakia (138-140). Paradoxically, oral 
Size >200mm2                                
Non-homogenous 
lesion                      
Lateral tongue lesion   
Non-smoking status 
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epithelial dysplasia has been found to have less malignant potential when associated with a 
smoking habit(9, 10).  
Despite a lack of randomised control trial evidence with regards to OED and smoking 
cessation/alcohol reduction, these habits are risk factors for the development of oral cancer 
and therefore smoking cessation advice and alcohol reduction counseling is advisable in the 
management of patients with OED(141).  It has been suggested that, for lesions thought to 
be at low risk of progression, e.g. mild/moderate dysplasia in a low-risk site, active 
monitoring may be the preferred management plan(140).  Active monitoring includes clinical 
examination, photographic records (15) and re-biopsy as guided by clinical change. Most 
clinicians would excise lesions showing evidence of severe dysplasia or carcinoma-in-situ as 
they would be considered at high risk of malignant transformation. A summary of recurrence 
and malignant transformation rates of OED treated by scalpel excision can be found in Table 
5.2.  
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Table 5. 2 Recurrence and Malignant Transformation Rates following Surgical 
Intervention for Oral Leukoplakia   
 
Non-surgical treatment would offer obvious advantages to patients and photodynamic 
therapy was reported to achieve a good response in one study (144); however, it is not a 
widely available modality and most studies have small sample sizes and insufficient follow 
up(145).  Chemoprevention (vitamin A, beta-carotene and 13-cis-retinoic acid) has been used 
in the management of OED but studies report early/high incidence of recurrence(146-148). 
Topical bleomycin has been shown to reduce the size of OED and reduce the severity 
histopathological grade compared to placebo (149). The latest Cochrane review regarding 
management of oral leukoplakia concluded that; there is insufficient high-quality evidence to 
support the use of non-surgical interventions for treatment of oral epithelial dysplasia(16).  A 
recent randomised control trial of freeze-dried black raspberry gel has shown promising 
Study 
cohort 
Type of 
Treatment 
Recurrence 
(%) 
 Malignant 
transformation rate – 
treated cases (%) 
Comments 
Pandey 
2001(142) 
Surgical 
Excision 
10.1 0 12 months 
follow-up 
Holmstrup 
2006(21) 
Scalpel 
Excision 
13.5 12.4 20% of 
malignant 
transformers 
were non-
homogenous 
lesions 
compared with 
3% 
homogenous 
Kuribayashi 
2012 (22) 
Scalpel 
Excision 
(with Lugol’s 
Iodine) 
15.1 1.9 Gingivae most 
common site for 
recurrence 
Thomas 
2012 (143) 
Scalpel 
Excision 
4.2 4.1 4.1% of lesions 
were on the 
tongue 
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short-term results for reduction in lesion size, grade of dysplasia and loss of heterozygosity 
events in OED lesions (26). 
In the UK, the British Association of Head and Neck Oncologists (BAHNO) Head and Neck 
Cancer Multidisciplinary Management Guidelines 2011 (150), advise on the targeted use of 
biopsy and histopathological assessment, along with advice on reduction of environmental 
carcinogens (tobacco use and alcohol), followed by surgical excision of the lesion where the 
size of the lesion and subsequent function allows (this was updated in 2016 without any 
change). The 2004 Fourth World Workshop on Oral Medicine have reviewed the 
management of oral epithelial dysplasia(55) and concluded that there is a lack of randomised 
studies assessing the effectiveness of surgical intervention in preventing malignant 
transformation.  However, surgical excision (laser or scalpel) remains the most 
appropriate/accessible treatment option for many patients.   
 
Surveillance of Patients with Oral Epithelial Dysplasia 
No consensus exists for exact duration of follow-up or follow-up intervals (15). Lifelong 
follow-up at intervals of no more frequent than every 6 months has been 
recommended(140). Recent evidence suggests that long term surveillance, up to 15 years, 
might be required(151). The BAHNO Management Guidelines have recommended long-term 
surveillance of OED (150). The majority of clinicians re-biopsy in the event of clinical 
deterioration of the lesion (152), however, a programme of scheduled re-biopsy may be 
justified in light of findings that clinically unsuspected OSCC have been detected as a result of 
scheduled re-biopsy (100).  
 The clinical setting used for surveillance may be significant for patient outcome: patients 
managed within the multidisciplinary oral dysplasia clinic, whose lesions underwent 
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malignant transformation, presented with significantly earlier stage cancers than those who 
presented via other routes(100).  This permitted more limited surgical intervention (wide 
local excision) and only occasional requirement for neck dissection, flap reconstruction and 
adjuvant radiotherapy, when compared to higher stage tumours presenting via other clinical 
pathways. 
It is however recognised that there is a significant economic cost attached to running these 
tertiary clinics, which may not be feasible to set up in some regions.  It may be reasonable to 
monitor lower risk lesions out with the multidisciplinary dysplasia clinic, but active 
surveillance would be required in either primary or secondary care. 
 
Whether, or not, it is acceptable in respect of risk management, to discharge patients 
considered in a ‘low risk’ cohort to primary care for review of their OED remains 
controversial, particularly in view of the ongoing uncertainties regarding the late risk of 
malignant transformation.  This approach would require close liaison between primary and 
secondary care and, ideally, the establishment of managed clinical networks. 
 
The Liverpool Multidisciplinary Approach to the Management of Oral 
Epithelial Dysplasia 
The establishment of the Multidisciplinary Oral Dysplasia Clinic 
 
The rationale for establishing the Liverpool Regional Oral Dysplasia Clinic was that, by 
concentrating on the combined expertise of senior clinicians from Oral & Maxillofacial 
Surgery, Oral Medicine and Oral Pathology, patient care would be enhanced, particularly in 
complex and high-risk cases.  This clinical environment would also create undergraduate and 
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postgraduate teaching and training opportunities and allow for the recruitment of patients 
into clinical studies which could inform future practice(83, 97, 100) and, ultimately, evidence-
based guidelines.   
When this clinic was first established referral criteria were agreed, as limited resources 
necessitated careful selection of cases.  Initially, patients with histopathology indicating 
either moderate or severe dysplasia were seen.  These had a range of clinical presentations, 
i.e. leukoplakia (including proliferative verrucous leukoplakia), erythroplakia, 
erythroleukoplakia and speckled lesions.  Patients were subsequently identified who had 
been attending Oral Medicine or Oral and Maxillofacial Surgery clinics and had a 
histopathological diagnosis of mild dysplasia, despite a clinically suspicious oral lesion, such as 
speckled leukoplakia. Targeted re-biopsy and specialist oral pathology review are indicated in 
these cases, following assessment on the multidisciplinary dysplasia clinic.   
It was also agreed that patients who had previously undergone ablative head and neck 
surgery would be followed up by the joint head and neck oncology team, rather than the 
dysplasia clinic, as they require follow up with several specialties including clinical oncology, 
speech therapy, dieticians, dentists and clinical nurse specialists. 
After twenty years of experience in both the multidisciplinary OED clinic and a routine Oral 
Medicine clinic, our approach to the management of OED has evolved and is now applied to 
patients referred from primary or secondary care.  Not all will be transferred to the 
multidisciplinary clinic, but the same approach to management is applied.  
Figure 5.1 illustrates an example of a management dilemma, with large lesions at the limits of 
what can be resected with good function outcome.  Geographic biopsies of the homogenous 
leukoplakia in a 70-year old man show mild dysplasia, however the patient is a lifelong non-
smoker and the predominant site is lateral tongue.  The patient has a similar but smaller 
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lesion on the contralateral tongue (and buccal mucosa).  Thus, with a balance of high and 
low-risk features, the decision on whether to intervene surgically or offer surveillance is finely 
balanced.  
 
Figure 5. 1 A clinical dilemma: Patient with lesions on tongue, demonstrating both high 
and low risk predictive factors for malignant transformation. 
 
The management algorithm of patients referred with OED to the Liverpool Oral Dysplasia 
Multidisciplinary Team, has been summarized in Figure 5.2. 
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Figure 5. 2 The Management Algorithm for cases of Oral Epithelial Dysplasia used by the 
Liverpool Multidisciplinary Team. 
 
Conclusion 
 
The management of patients with OED remains problematic and poses significant challenges 
to the clinician. Risk stratification for malignant transformation currently relies on the clinical 
and histological features. 
It is acknowledged that the principles underlying the Liverpool Multidisciplinary approach to 
OED are not new or unique. However, this has formed the basis of the management of OED 
in a tertiary supra-regional practice and led to excellent survival outcomes(100). Whilst the 
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establishment of a multidisciplinary specialist clinic would be the ideal to strive towards and 
should be encouraged, the management of OED, in a considerable proportion of cases, is still 
based in secondary care, either in Oral Medicine or, Oral and Maxillofacial Surgery. The 
principles that underlie the Liverpool Approach could be transferable to other clinical 
settings, supported by fast-track referral to a Head & Neck cancer team as needed, thus 
allowing timely management of patients undergoing malignant transformation. 
 
Referral of Patients with suspicious oral lesions 
 
Most patients are referred from primary dental care and have potentially malignant oral 
mucosal lesions identified from opportunistic screening.  Referrals from primary medical care 
are often prompted by the patient’s self-examination.  Some referrals are via the 2 Week 
Head & Neck Suspected Cancer Pathway; others are triaged from referral letters as needing 
Urgent (within 2 weeks) or Priority (within 6 weeks) appointments. 
 
Assessment of Patients 
 
A comprehensive history including medical, smoking (and/or betel quid use), alcohol, social 
and dental history should be documented. After extra-oral examination, the oral mucosa is 
carefully visualised with attention paid to the floor of mouth, lateral borders of the tongue 
and oropharynx, as these areas can be more difficult to examine.  Fibreoptic nasendoscopy is 
arranged for any patients where visualisation of the affected mucosa is difficult.  All mucosal 
lesions are photographed, with requisite labelling of patient details, and the appearance of 
lesions, as well as results of palpation.  The importance of taking an adequate and 
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representative tissue sample cannot be over-emphasised and if necessary, the biopsy site is 
marked on a print-out of the clinical photograph.  In complex and non-homogenous lesions, 
the biopsy site is chosen by a senior, experienced clinician; this is not devolved to a trainee 
without close supervision.  Biopsies close to or overlapping opening of salivary ducts are 
undertaken by an Oral and Maxillofacial Surgery consultant. 
Larger lesions (>200 mm2) usually require multiple geographic biopsies and for these, and 
posterior-placed lesions, a general anesthetic (or intravenous sedation) is considered and 
discussed with the patient. 
 
The General Management of Patients with Oral Epithelial Dysplasia 
 
Patients are counselled about smoking cessation and offered appropriate access to support.  
Their alcohol intake is also addressed.  The biopsy result(s), indicating the level of dysplasia as 
well as the clinical appearance of the lesion(s), influences the management approach and 
these factors, together with any possible surgical interventions, are discussed with the 
patient and family or carer, as appropriate.  Patient factors such as co-morbidities and frailty 
are considered, but paramount are the patient’s wishes and their informed consent to any 
procedures.  The following approach is adopted in Liverpool in respect of histopathological 
findings and clinical presentation.   
 
Severe Dysplasia 
 
Patients are offered surgical excision with the aim of achieving clear margins.  For extensive 
lesions, essentially deemed unresectable, excision is not compatible with function, therefore 
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active surveillance with re-biopsy is undertaken.  This policy is sometimes needed even for 
high risk lesions. The application of toluidine blue or Lugol’s iodine is considered to aid 
visibility of dysplasia during surgical excision/ablation.  In higher risk cases, reconstruction 
with skin graft, local flaps or microvascular free tissue transfer is considered; these patients 
are referred to Head and Neck MDT for imaging and management decisions.  
 
Moderate Dysplasia 
 
Excision is considered for some patients, providing the lesion is not too extensive to allow 
acceptable post-operative function. Patients with high risk lesions (see Table 5.1) are 
recommended to have surgical intervention.  For those patients without high risk factors, a 
period of active surveillance, with re-biopsy in the event of clinical change, may be 
considered.  A decision concerning patients with co-morbidities or who are not willing to 
have any surgical / laser intervention can be similarly delayed and management options re-
visited. 
 
Mild Dysplasia 
 
Patients with homogenous oral mucosal lesions and a histopathological diagnosis of mild 
dysplasia are offered surveillance, together with smoking cessation and alcohol-related 
advice, as appropriate.  If the oral lesion has high risk features (Table 5.1) then re-biopsy is 
undertaken, or a decision made to proceed directly to excision. The latter would usually be 
preceded by a detailed discussion with the patient and their clear expressed informed 
consent.  
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Surveillance of Patients with Moderate or Severe Dysplasia 
 
Patients with severe or moderate dysplasia are followed-up in the multi-disciplinary clinic on 
a long-term basis, regardless of whether there has been surgical or laser treatment.  They 
undergo a full assessment at each review, and this includes up-to-date clinical photographs.  
A decision is made concerning the need for follow-up biopsy (or biopsies), this is primarily 
prompted by clinical concerns about the change in appearance of the lesion (or lesions) and 
involves a team approach.  If the patient reports (rare) discomfort from a previously 
asymptomatic lesion under surveillance, this is regarded as a red flag (warning symptom) 
unless there are obvious causative factors, such as trauma from a loose denture or teeth.  
The follow-up interval is usually one-month post-surgery/laser excision and then 3, 6 or 12 
monthly depending on the clinical assessment, histology and previous history. 
Surveillance and Follow-up of Patients with Mild Dysplasia 
 
Most patients with mild dysplasia are reviewed in the routine Oral Medicine or Oral and 
Maxillofacial Surgery clinic, i.e. secondary care, for up to 5 years.  If their lesion undergoes 
significant changes, or following a repeat biopsy indicating a higher grade of dysplasia, they 
are referred to the multidisciplinary OED clinic.  Some patients with mild dysplasia and high-
risk clinical features will also be offered long term review in the routine Oral Medicine clinic. 
A decision concerning referral back to primary or secondary care for ongoing surveillance is 
made based on several factors, including past dental history and attendances, patient 
preference and liaison with the patient’s general dental practitioner.  If the patient and 
dentist are involved in this decision and provided with all copies of relevant histopathology 
and updated photographs, this can be a mutually beneficial option for follow-up.  It is 
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essential that both the patient’s general dental and medical practitioners are kept informed 
of the patient’s progress from their first hospital visit.  Safeguards for this arrangement 
include copying the discharge letter to the patient so they are aware of the need to attend 
their general dental practitioner for follow-up and providing the general dental practitioner 
with the appropriate contact details so re-referral can be promptly arranged if concerns arise 
with the oral mucosal lesion. 
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Chapter 6 Loss of FANCD2 and related proteins may predict 
malignant transformation in oral epithelial dysplasia 
Introduction 
 
In the management of oral epithelial dysplasia (OED), histopathological grading and clinical 
determinants of malignant transformation to oral squamous cell carcinoma (OSCC) have been 
the primary influence in the treatment approach adopted (20, 55, 97), despite the numerous 
studies identifying putative molecular and other predictors of malignant change (28, 135, 
153). Most studies aimed at identifying a molecular or pathological marker of malignant 
change have failed to undertake correlation with longitudinal clinical outcomes, so their 
translational value has been diminished leading to the lack of clinical application (23-25). 
Furthermore, they have mostly not been formally validated in independent series - this 
approach is difficult as the event rate of malignant transformation is low, and studies are 
therefore prolonged (3). There is a notable paucity of multi-centre/collaborative protocols, 
and, where malignant transformation can be predicted, there remains some uncertainty 
about recommended treatment options. The clinical outcomes of a cohort of patients 
managed in the Liverpool Multidisciplinary Oral Dysplasia Clinic, identified non-smoking 
status and the non-homogenous appearance of OED as the strongest independent predictors 
of malignant transformation (HR 5.9 and 2.3 respectively) (97). The estimated malignant 
transformation rate in this study was 22% over 5 years. The more aggressive behaviour of 
lesions observed in non-smoking patients (or light smokers) with OED supports an 
endogenous aetiology: while this might seem counter-intuitive, this trend has been seen in 
other models of carcinogenesis (154, 155).  
The incidence of head and neck squamous cell carcinoma (HNSCC) in patients with the cancer 
prone syndrome, Fanconi Anaemia, is 1400 times greater than that of the general population 
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(31, 32) and occurs earlier in life. The Fanconi Anaemia pathway (FAP) removes interstrand 
crosslinks (ICL) lesions and facilitates homologous recombination repair of DNA double-
strand breaks and is an integral component of the DNA damage repair mechanism which 
maintains genomic stability in healthy individuals (34, 35, 52). The FAP consists of 22 proteins 
(FANCC – FANCW) and has 3 main components (41) (Figure 1.1): (i) The FANCM-MHF1-MHF2 
complex senses ICLs and localises to the DNA, acting as a recruitment site for the core 
complex through FANCM-FANCF interactions. The main role of the core complex is to 
facilitate ubiquitination of (ii) FANCD2 and FANCI protein dimers. The core complex mediates 
FANCD2/FANCI monoubiquitination, at residues K561 and K532 through FANCL E3 ubiquitin 
ligase activity, which then activates (iii) downstream effector proteins which include 
nucleases, translesion polyermases, homologous recombination proteins, and de-
ubiquitinases to complete the DNA repair process and to attenuate FAP signalling. The 
detection of prognostic markers of DNA damage such as single-stranded DNA and replication 
stress, leads to the ataxia telangiectasia rad–3 (ATR) and checkpoint 1 (CHK1) kinases 
mediated cell cycle arrest in G2 or S phase, and activation of key components of the FA 
pathway via phosphorylation at several functional residues, including; FANCA at S1449, 
FANCM at S1045, FANCD2 at S717, S222, S331 and T691, FANCG at S387, S383 and S7, and 
FANCE at S374 and T346. (44-47).  
If left unrepaired, ICL lesions progress through the cell cycle, resulting in the stalling of 
replication forks and the eventual formation of double-strand breaks, resulting in genomic 
instability. (156). 
We hypothesise that in transforming OED (particularly in non-smokers), an aberration in the 
DNA damage sensing, signalling or repair pathways leads to accumulation of DNA mutations 
and malignancy. These aberrations in the tumour suppressor mechanism leads to 
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phenotypical and genotypical changes which occur in the early phase of carcinogenesis. In 
OED, the potential exists for identification of these aberrations in these lesions with potential 
for malignant transformation.  The objective of this study was to investigate the status of 
FANCD2 and related proteins (ATR, Chk1 and FANCG) in the DNA damage repair pathway of 
OED in patients who presented to the Liverpool Multidisciplinary Oral Dysplasia clinic, 
specifically to elucidate if this information could be obtained from the initial diagnostic biopsy 
as a predictive tool which might have been utilised to influence clinical management, and to 
correlate these findings to clinicopathologic characteristics.  
 
Patients, materials and methods 
 
Patients  
Forty patients with OED, were identified from the clinical cohort in Chapter 2 and were 
included in this study after giving informed consent. All specimens for this study additionally 
met the additional criteria that the diagnostic FFPE block had not been previously utilised for 
translational research. The tissue size on the diagnostic biopsy FFPE block allowed for four 
0.6mm core to be extracted for RNA extraction/Western blotting (23 non-transforming OED – 
NT and 17 malignant transforming OED – T). Four micrometre sections of the initial 
diagnostic incisional biopsy FFPE from each patient were stained with haematoxylin and eosin 
(H&E) and reported blinded and independently by two oral and maxillofacial pathologists to 
confirm the presence of OED (Initial attempts to construct a tissue micro-array was 
unsuccessful as the thickness of the incisional biopsy FFPE specimen was variable and 
inadequate to allow reproducibility of sections which enabled consistent and meaningful 
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comparison(23)). In this study, the WHO 2017 dysplasia classifications(2) were then grouped 
as follows: Group 0: severe dysplasia and Group 1: mild or moderate dysplasia  
FANCD2 Immunohistochemistry  
 
FFPE sections from each clinical timepoint, including the initial diagnostic biopsy, for these 40 
patients were stained with anti-FANCD2 antibody (F117: sc-20022, Santa Cruz diluted 1/100) 
and Biogenex Supersensitive Polymer HRP detection kit (Launch Diagnostics QD430-XAKE) as 
previously described(155). The expression of FANCD2 was scored blinded by two 
independent observers (Asterios Triantafyllou and Michael Ho), one being an oral and 
maxillofacial pathologist. The stained sections were identified by their pathology 
identification number alone, thus the observers were blinded to the clinical details and 
outcome of OED i.e. either stable OED or OED which underwent malignant transformation. 
Consequently, staining was classified by localisation, extent and intensity using a descriptive 
binary scoring system (Table 6.1). Any discrepancy in scoring was reviewed jointly and a 
mutually agreed score determined. Control tissue from normal and OED areas of tissue 
adjacent to OSCC from a different cohort of anonymised patients (n=3) were stained using 
the same method.  
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Feature Binary score 
 0 1 
Nuclear  
Staining 
Extent Absent-Focal 
Multifocal-
Widespread 
Intensity Absent-Weak 
Moderate- 
Strong 
Cytoplasmic 
Staining 
Extent Absent-Focal 
Multifocal-
Widespread 
Intensity Absent-Weak 
Moderate- 
Strong 
 
Table 6. 1 FANCD2 immunohistochemistry scoring system 
Western blotting  
 
Areas with the highest grade of dysplasia in the incisional biopsies were marked on the H&E 
stained sections and 0.6mm cores were obtained from the corresponding FFPE blocks 
(minimum of 2 cores from each block).  Cores of the same diameter were obtained from 
anonymised controls as follows: normal tissue from oesophagus (n=5), areas of OSCC from a 
different cohort (n=3) and tissue with normal histological architecture located adjacent to 
OSCC (n=3). 
The protein extraction protocol utilised was modified (based on local expertise from 
supervisor J. B. Wilson) from one previously published (157):  FFPE cores were placed in 
Eppendorf safe‐lock tubes (Eppendorf, Hamburg, Germany) and deparaffinised by incubation 
at room temperature in xylene for 10 min. After each incubation, the tissue was pelleted at 
12 000×g for 3 min, and incubation/centrifugation steps were repeated two more times. The 
deparaffinised tissue pellets were then rehydrated with a graded series of ethanol (100% for 
5 minutes, 90% for 5 minutes, 70% for 5 minutes and a further 5 minutes in 70%) and 
centrifuge at 1300 RPM for 30 secs to remove excess ethanol. Following this, 150µl of 
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Laemmli sample buffer (Sigma-Aldrich) were added. All samples were subjected to high‐
temperature extraction at 100°C for 20 min, and then cooled in ice for 5 minutes. Extracts 
were centrifuged for 30 min at 13000 RPM and the supernatant collected and stored at −20°C 
until needed.  
The expression of β-actin, ATR, pATR (s428), CHK1, p-CHK1 (s317), FANCD2 (non-and mono-
ubiquitinated isoforms), pFANCD2 (s331), FANCG and pFANCG (s7) were assessed in a 
blinded fashion (to clinicopathologic details and outcome: stable OED or OED which 
underwent malignant transformation) by western blotting using anti- mouse or anti-rabbit 
fluorescently labelled 680/800 secondary antibodies (1:10 000 dilution) (Invitrogen, Paisley 
UK) (Table 6.2) (43), extracted protein was separated on SDS- polyacrylamide (PAGE) gels: 
samples were prepared for loading, by the addition of 20 μL of protein extract to 40 μL of 
Laemmli loading buffer and immediately heated at 100 °C for 5 minutes, prior to loading. The 
samples were loaded on to a 15% SDS-PAGE gel which were ran overnight at constant 50 V. 
The protein was then transferred to a nitrocellulose membrane - 4 hours at constant 350 mA 
(158). This was blocked in LI-COR buffer for 1 hour at room temperature prior to the addition 
of specific antibodies at the specified dilutions.  
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Antibody 
against 
Raised in Company Catalogue number Dilution 
Citations 
β-actin (C4) Mouse Santa Cruz sc-47778 1:5,000 (159) 
ATR Rabbit Atlas HPA028264 1:1,000 (160) 
pATR Mouse Gift of Dr G. M. Kupfer 1:1,000 (43, 51) 
CHK1 Mouse Santa Cruz sc-56291 1:1,000 (161) 
pCHK1 (S317) Rabbit Calbiochem DR1025 1:1,000 (161) 
FANCD2* Mouse Santa Cruz sc-28194 1:500 (46) 
pFANCD2* 
(S331*) 
Mouse Gift of Dr G. M. Kupfer  1:1,000 
(43, 51) 
FANCG* Rabbit Santa Cruz sc-28219 1:1,000 (46) 
pFANCG* (S7*) Mouse Gift of Dr G. M. Kupfer  1:1,000 (51, 162) 
*selected as markers of activation of the Fanconi Anaemia pathway availability and reliability 
from previously published data(43, 53) 
Table 6. 2 Antibodies used in Western blot 
 
An Odyssey Infrared Imaging System was used to visualise band intensity (Li-Cor Biosciences, 
Cambridge, UK). Densitometry values of band intensities were measured and calculated using 
ImageJ®. For each protein, these values were normalised against the oesophageal normal 
tissue scores (positive FANCD2 expression 
(https://www.proteinatlas.org/ENSG00000144554-FANCD2/tissue), anonymised normal 
tissue readily available), then ranked and divided into tertiles representing low expression, 
moderate expression and high expression. The normal oesophageal control values always lay 
within the central tertile.  
 
Data/Statistical Analysis 
 
Mann Whitney and Fisher exact tests were utilised to compare FANCD2 
immunohistochemistry scores between samples from NT and T OED lesions. The Fisher-
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Freeman-Halton exact test was used as a measure of significant difference and comparison 
between the densitometry ratios of NT and T OED samples. Statistical analyses were 
conducted, using the statistical software (IBM SPSS Statistics for Windows, Version 22.0). A p 
value of less than 0.05 was considered significant. 
Results 
 
Patient outcomes  
The demographic and clinicopathologic details of the forty patients included in this study are 
summarised in Table 6.3.  
As previously noted in Chapter 2, the malignant transforming (T) group had a higher 
proportion of non-smokers (p =0.05), lateral tongue lesions (p = 0.01) and non-homogenous 
OED (p = 0.001) when compared with the non-transforming (NT) OED group. The median 
follow-up period was 5.3 years (range 0 - 21 years) with a median of 3.4 years (range 0 - 14 
years) for the NT group and 6.9 (range 1 – 21 years) for the T group. The median time to 
malignant transformation was 3.4 years (range 0 – 7.6 years).  The dysplasia binary score at 
first diagnostic biopsy was not significantly different between the groups, with 5/17 (29%) 
transformers classified as high risk compared with 3/23 (13%) non-transformers (P=0.189). 
These 3 patients were progression-free for 18, 52 and 107 months, respectively, following 
diagnosis. The median time to malignant transformation for T OED in patients with the higher 
risk binary score at diagnosis was 14.8 months when compared with T OED with a low risk 
binary score, 44.7 months (p = 0.1).  
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Table 6. 3 Demographic and clinic-pathological features of patients (n = 40) (* at initial 
diagnostic biopsy) 
 
 
 
 
Non-
transformers 
(n =23) 
Transformers 
(n=17) 
P value 
 
Age Median (range) 55.9 
(27.9 – 78.4) 
57.5  
(37.5-85.2) 
0.56 
Gender  
n (%) 
Male 
Female 
13 (57) 
10 (43) 
6 (35) 
11 (65) 
0.22 
Site  
n (%) 
Lateral tongue 
Floor mouth 
Buccal 
Alveolar mucosa 
4 (17) 
11 (49) 
4 (17) 
4 (17) 
10 (58) 
3 (18) 
4 (24) 
- 
0.01 
Appearance  
n (%) 
Homogenous white 
Red-white 
Red 
20 (87) 
2 (9) 
1 (4) 
7 (41) 
10 (59) 
- 
0.001 
Lesion size   
n (%) 
< 200mm2 
> 200mm2 
5 (22) 
18 (78) 
3 (18) 
14 (82) 
1 
Smoking  
n (%) 
Never  
5-20 pack years 
>20 pack years 
5 (22) 
7 (30) 
11 (48) 
7 (41) 
8 (47) 
2 (12) 
0.05 
Alcohol  
n (%) 
Teetotal 
Current drinker 
6 (26) 
17 (74) 
5 (29) 
12 (71) 
1 
Grade of 
dysplasia* 
n (%) 
Mild/moderate 
Severe/Cis 
20 (87) 
3 (13) 
12 (71) 
5 (29) 
0.19 
Definitive 
treatment  
Surveillance 
Excision 
17 (74) 
6 (26) 
0 
17 (100) 
0.0001 
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FANCD2 immunohistochemistry 
 
Nuclear and cytoplasmic staining for FANCD2 was absent in morphologically normal oral 
epithelium (Figure 6.1), however, FANCD2 staining increased in intensity in non-invasive 
dysplastic epithelium and was then lost again in micro-invasive OSCC (Figure 6.1).  
A decrease in the intensity of both nuclear and cytoplasmic staining were observed in the 
first diagnostic biopsy of OED lesions that were destined to undergo malignant 
transformation when compared with non-transforming OED, although the distribution of 
staining was not statistically different (the quantitative, rather than qualitative, element of 
FANCD2 staining was predictive of malignant transformation) (Figure 6.2; Table 6.3).  
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Figure 6. 1 Representative example of FANCD2 immunohistochemistry during progression 
to carcinoma. A: lack of FANCD2 expression in normal (non-dysplastic) epithelium; 
widespread and moderate staining in the nucleus and cytoplasm of suprabasal 
(differentiating) layers in non-invasive dysplastic epithelium and B: loss of FANCD2 expression 
when malignant transformation has occurred. Magnification x400 
 Non-dysplastic epithelium 
Non-invasive dysplastic 
epithelium 
A 
B 
Non-invasive dysplastic 
epithelium 
Micro-invasive squamous cell carcinoma 
epithelium 
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Figure 6. 2 Representative FANCD2 immunohistochemistry of ‘low risk’ dysplasia from 
NT OED (left): moderate dysplasia displaying strong nuclear and cytoplasmic expression of 
FANCD2 across the entire thickness of epithelium with widespread distribution and ‘high 
risk’ T OED (right): severe dysplasia with weak and irregular expression FANCD2 in the 
nucleus and cytoplasm of especially in the basal two-thirds of the epithelium with multifocal 
distribution  . Top row : low power magnification (x100); bottom row: high power 
magnification (x400).  
 
Therefore, only intensity scores were incorporated into a final composite FANCD2-OED score 
as below. In OSCC sections from transformed OED lesions, both intensity and distribution of 
FANCD2 staining were reduced compared with the first diagnostic biopsy from the same 
patient (Table 6.4).  
 
 
 
97 
 
  Biopsy 
 
Site of staining 
 
Pattern of staining 
NT - first 
diagnostic 
n (%) 
T – first 
diagnostic 
n (%) 
T – OSCC 
diagnostic 
n (%)* 
Nuclear Distribution    
 Absent/Focal 6 (26) 4 (24) 9 (60) 
 Multifocal/Widespread 17 (74) 13 (76) 6 (40) 
 Intensity**    
 Absent/Weak 13 (57) 16 (94) 14 (93) 
 Moderate/Strong 10 (43) 1 (6) 1 (7) 
Cytoplasmic  Distribution    
 Absent/Focal 1 (4) 1 (6) 4 (27) 
 Multifocal/Widespread 22 (96) 16 (94) 11 (73) 
 Intensity***    
 Absent/Weak 5 (22) 8 (47) 10 (67) 
 Moderate/Strong 18 (78) 9 (53) 5 (33) 
*Specimens for two patients were not retrievable from archival records 
**: NT v T (first diagnostic biopsy) P<0.008 (Mann-Whitney Test) 
***: NT v T (first diagnostic biopsy) P=0.089 (Mann-Whitney Test) 
 
Table 6. 4 FANCD2 immunohistochemistry scores in first diagnostic biopsy of non-
transforming (NT) and transforming (T) OED, together with paired OSCC for the transforming 
group 
Combining the FANCD2 nuclear and cytoplasmic intensity scores with the histological grading 
of OED (mild/moderate dysplasia assigned score of 1 and severe dysplasia/carcinoma-in-
situ/SCC assigned score 0) produced a score that more accurately predicted transformation 
(p=0.005) (Table 6.5), with a cut off score of 1 or less being significantly associated with a 
higher risk of malignant transformation in OED (p=0.001). This FANCD2-OED Risk Score in all 
the retrieved OSCC archival tissue from OED which underwent malignant transformation was 
<1 (n = 15; 2 archival OSCC specimen not retrievable). 
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FANC D2–OED Risk 
Score  
NT OED 
n = 23 
T OED 
n = 17 
P value 
(Mann 
Whitney 
test) 
*P Value 
(Fisher’s 
exact test 
3 4 21* 2 7* 
0.005 
 
 
0.001 
2 17 5 
1 2 2* 8 10* 
0 0 2 
FANC D2–OED Risk 
Score 
 OSCC 
n = 15 
 
1   7 15 
0   8 
 
Illustration of how FANCD2-OED Risk Score was derived: 
e.g. Severe dysplasia (0) with absent/weak nuclear staining (0) and moderate/strong 
cytoplasmic stain (1) = 0 + 0 + 1 = 1 
 
Table 6. 5 FANCD2 IHC-OED grade combined scores in stable OED (NT), OED which 
underwent malignant transformation (T) and oral squamous cell carcinoma which had arisen 
from OED. 
Of the 2 NT OED lesions with low (≤1) FANCD2-OED Risk scores, one patient presented with 
severe dysplasia which was excised shortly after presentation and has now been progression 
free for 52 months and one presented with mild dysplasia that has been progression-free for 
19 months. Eighty-three percent (10/12) of patients with FANCD2-OED Risk score ≤1 in the 
OED cohort reported went on to develop OSCC compared with 25% (7/28) in patients with a 
score of ≥2. The diagnostic biopsies for the 7 transforming lesions with high (≥2) FANCD2-
OED Risk scores were obtained a median of 5.8 years (range 0.3-7.0 years) prior to 
transformation, while the biopsies from the 10 transforming lesions with low (≤1) scores 
were taken a median of 2.4 years (range 0.2-5.3 years) prior to transformation. In all 15 of 
the available oral squamous cell carcinomas which had arisen from OED, the expression of 
FANCD2, and the concomitant FANCD2-OED score, was low (Table 6.5). The FANCD2-OED 
scores were not significantly different when the following parameters were assessed: age, 
gender, site of lesions, appearance of lesion, smoking or alcohol history and time to 
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transformation, but as expected, were associated with grade of dysplasia (P<0.0005). In total, 
1/3 ‘false positive’ and 5/12 ‘false negative’ dysplasia grade scores were correctly predicted 
by the FANCD2-OED score.  
FANCD2 and associated protein expression 
 
No significant differences in the normalised expression of β-actin, ATR, CHK1 and FANCG 
were observed between T and NT OED lesions (Table 6.6; Figure 6.3). As the biopsy 
specimens in OED were much smaller in comparison with those obtained in established 
OSCC, the Western blots were performed on a single occasion due to the limited quantity of 
available protein.   
However, significantly reduced expression of FANCD2 (non-ubiquitinated and mono-
ubiquitinated forms), pFANCD2, pATR, pCHK-1 and pFANCG were observed in OED prior to 
malignant transformation with the FANCD2, pFANCD2 and pFANCG observations mirrored in 
the control tumour tissue. These parameters did not correlate with any clinicopathological 
features such as site or smoking history. The median ratio of mono-ubiquitinated: non-
ubiquitinated forms of FANCD2 (an indication of activation of the FA pathway) were 0.9 and 0 
for NT and T OED, respectively (p < 0.001).  
 
 
 
 
 
100 
 
Normalised densitometry 
score ratio* 
Low 
expression 
n (%) 
Moderate 
expression 
n (%) 
High 
expression 
n (%) 
P value 
(Fisher-Freeman-
Halton exact test) 
ATR T 
NT 
9 
7 
3 
8 
5 
8 
0.24 
pATR  T 
NT 
14 
1 
3 
9 
0 
13 
< 0.0005 
Chk1 T 
NT 
5 
10 
7 
5 
5 
8 
> 0.29 
pChk1  T 
NT 
13 
3 
3 
8 
1 
12 
< 0.0005 
FANCD2 (S & L#) T 
NT 
10 
10 
2 
8 
5 
5 
< 0.025 
pFANCD2-s331  T 
NT 
16 
1 
1 
12 
0 
10 
< 0.0005 
FANCG T 
NT 
4 
10 
6 
4 
7 
9 
0.61 
pFANCG-s7 T 
NT 
16 
1 
1 
10 
0 
12 
< 0.0005 
* See materials and methods 
# Sum of ‘small’ and ‘large’ FANCD2 isoforms. - L corresponds to the 
monoubiquitylated (activated) isoform p: phosphorylated proteins; s331 & s7: 
location of phosphorylation  
 
Table 6. 6 Normalised protein expression in initial diagnostic biopsy of NT OED and T 
OED lesions  
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Figure 6. 3 Representative example of Western blot expression analysis of DNA damage 
sensing and repair proteins. NT: first diagnostic biopsy of a non-transforming OED; T: first 
diagnostic biopsy of a transforming OED; Oe: normal oesophagus; CT: control OSCC from a 
different cohort; CN: control (morphologically) normal from margin of OSCC resection.   
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Discussion 
 
The results and observations of this study have evidenced support to the notion that loss of 
FANCD2 and associated protein (in the DNA damage repair pathway) are associated with 
malignant transformation in OED. The lower, statistically significant, expression of post-
translationally modified proteins in T OED when compared to NT OED is indicative of 
inactivation of the pathways and was a more accurate predictor of malignant transformation 
than clinical parameters such as smoking history and site. Furthermore, 
immunohistochemical staining for FANCD2 coupled with a binary dysplasia score could 
correctly predict malignant transformation in 10/17 initial biopsy samples obtained prior to 
transformation, with a ‘false positive’ rate of 2/23 non-transforming OED biopsies. This 
performed better than dysplasia grading alone, either as a binary score or the current WHO 
classification. The significantly different rates of malignant transformation in between 
patients with low FANCD2 (83%) expression and higher FANCD2 (25%) expression further 
validate its potential utility in the clinical setting in determination of the risk of 
carcinogenesis.   The data of Rudland et al (155) indicates that cytoplasmic as well as nuclear 
staining may be prognostic, but their complicated system for scoring extent and intensity of 
staining was not appropriate for our samples which were generally small in nature. There 
could be scope for future validation studies to utilise resection specimens if necessary, 
however there is generally some degree of heterogeneity in tissue architecture/grade of 
dysplasia and interpretation of these findings require further thought and definition of the 
scoring criteria utilised. Both CHK1 and CHK2 phosphorylate the FANCD2 protein at different 
sites, but only phosphorylation of the s331 residue activates the protein complex. Upstream, 
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the ATR pathway is of interest because when CHK1 is phosphorylated, it in turn activates 
FANCD2 by phosphorylation. 
The loss of FANCD2 expression has to be viewed within the context of the presence of OED or 
OSCC, hence the importance of including the grade of OED (or diagnosis of OSCC) into the 
FANCD2-OED Risk Score (Table 6.5). In several anonymised normal oesophageal control 
samples(Figure 6.3) the expression of FANCD2 was not observed similar to the normal oral 
epithelium (obtained from the margins of resected OSCC/OED specimen) (Figure 6.1A). This 
suggests that in the absence of OED or OSCC, the lack of FANCD2 expression would indicate 
that the Fanconi Anaemia Pathway has not been activated. The difference in these normal 
controls with transforming OED is that quite consistently the post-translational modifications 
e.g. pATR, pChk1, pFANCD2(s331) and pFANCG(s7) have all been preserved in the control 
specimen. These warrants further investigation in order to explain the mechanism of the 
Fanconi Anaemia Pathway in normal and diseased tissue within the context of the process of 
carcinogenesis. 
In this analysis, moderate dysplasia was classified together with mild dysplasia as ‘low risk’ 
while severe dysplasia was classified as ‘high risk’. Other researchers have classified 
moderate dysplasia as ‘high risk’, but recent discussion in the literature suggests that both 
suggested binary classifications are simplistic (125, 163). Alternative suggestions for binary 
classification of oral dysplastic lesions rely heavily on pathological interpretation, which could 
be prone to intra and inter-observer reliability problems (164, 165). It is acknowledged, 
therefore, that the proposed histopathology/IHC classification in its current format will have 
skewed the moderately dysplastic lesions in this study towards higher FANCD2-OED scores 
and is thus prone to false negatives, although it still performed better than histopathology 
alone. Its strength may be in identifying lesions which will NOT transform, but development 
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into a routine, clinical test requires a more robust definition of reduced immunostaining 
utilising data from a larger number of transforming and non-transforming lesions. This study 
is best categorised as proof-of-concept as the design and the cohort are not adequate for a 
robust prognostic biomarker study. 
When the NT and T groups were compared, there were significant differences in site, 
smoking aetiology and appearance between the two cohorts. These are such strong 
predictors of transformation in our modest cohort that it was impossible to adequately 
match the two groups.  The validity of diagnosis of the grade of OED from an incisional biopsy 
could potentially be questioned as the issue of heterogeneity of OED especially in a large 
lesion is a valid consideration. In the Liverpool Oral Dysplasia MDT clinic, the biopsy of OED 
lesions is carried out by senior surgical members of the team where the area of most clinical 
concern is sampled. Experience in our practice would suggest that concordance of  initial 
biopsy and definitive histopathology diagnoses were very high and had not adversely 
impacted on patient outcomes. This was demonstrated in the reported cohort of patients 
where patients who have their OED excised did not have their grade of OED upgraded but 
the more often scenario was that the area with the most severe grade of OED has been 
completely excised by the incisional biopsy. Therefore, the findings observed for FANCD2 
immunohistochemistry and Western blotting were valid from the statistical and clinical 
perspectives.  
Six of the twenty-three NT lesions (that we would have expected to transform) were totally 
excised – therefore some of the differences observed between NT and T groups might 
potentially relate to the method of treatment rather than the inherent cancer risk of the 
sample (Table 6.3) This could be a reflection that there is such strong prescription bias on 
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grade and/or clinical features of lesions that it would be impossible to adequately match the 
cohorts. 
The median follow-up period was less in the NT vs the T group [3.4 years (range 0 - 14 years) 
vs 6.9 (range 1 – 21 years)], and this may partially explain the observation of NT OED lesions 
with low (≤1) FANCD2-OED scores, one of whom had only been followed for 19 months, and 
T OED lesions with high (≥2) FANCD2-OED scores, 6 of which were obtained more than 3 
years prior to transformation. These data may give some indication as to the sensitivity of 
this technique for prediction of malignant transformation prior to the event. For example, of 
the 6 T OED patients in whom we had non-neoplastic tissue from an intermediate timepoint, 
we observed that the FANCD2-OED scores decreased in 2 patients (from ≥2 to ≤1 in both 
cases) and remained static in 4 patients (3/4 of whom scored ≤1 at the initial biopsy), with all 
the OSCC from these patients scoring 0 (n=5) or 1 (n=1).  
 
It has been reported that phosphorylated proteins are more labile, and that epitope 
degradation can occur within 30 minutes of ischaemia in formaldehyde (166) leading to loss 
of certain post-translational modifications (PTMs), specifically phosphorylation. Utilising the 
protein extraction protocol described in this study, the expression of PTMs has been shown 
to be consistently down-regulated across 4 different phosphorylation sites (ATR (s428), CHK1 
(s317), FANCD2 (s331) and FANCG (s7)) in biopsy tissue destined to transform (T-OED) 
compared with that which was not (NT-OED). This finding is significant given the lack of 
availability of fresh tissue collections from cohorts of dysplasia patients and suggests that 
PTM biomarkers of transformation may be developed for FFPE tissue.  This could potentially 
be used to influence treatment decisions in clinical practice or when utilised within the 
context of a clinical trial in the management of OED to stratify treatment/intervention arms. 
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The hypothesis that malignant change in OED involves alteration of the FA pathway is 
supported by both our immunohistochemistry and western blotting data. These reinforce the 
previously described differences observed in the appearance and site of OED in these two 
groups of patients(97) but are not simply a reflection of these differences as no associations 
were observed between site or appearance of lesion and PTM of these proteins. Samples 
from T OED lesions showed significant reduction in the phosphorylation of ATR, CHK1, 
FANCD2 and FANCG in comparison to non-transforming samples, indicating a lack of ATR-
CHK1 activation following DNA damage and/or replicative stress. It may be argued that these 
observations are due to a lack of stimuli in the transforming group as they have a 
preponderance of non-smokers, but analysis of our data does not support this as no 
significant difference in PTM expression was observed between smokers and non-smokers. 
The ability of CHK1 to phosphorylate several functionally important sites for optimal function 
and activation of the FA pathway appears to be compromised in these patients which, it is 
proposed, will lead to the impairment of the functionality of the FA core complex and lead to 
a reduction in subsequent HRR activity (43, 46, 51, 167). In contrast, non-transforming 
samples showed high levels of FANCD2 s331 and FANCG s7 phosphorylation, indicating that 
these sites were successfully phosphorylated by activated CHK1, and could function 
effectively in DNA repair, thus reducing the burden of DNA damage in these cells and 
reducing the risk of malignant transformation.  
FANCD2 monoubiquitylation, which is thought to be promoted by ATR-CHK1 mediated 
FANCD2 phosphorylation (45, 161), is a critical step in FA pathway activation(51, 168) and 
evidence suggests that a reduction in FANCD2 monoubiquitylation has a greater influence on 
genomic instability than down regulation of FANCD2 expression (169). In our study, it was 
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observed that transforming samples have lower levels of FANCD2 monoubiquitylation 
(FANCD2 L expression) compared to non-transformers, and interestingly, they consistently 
displayed lower levels of total FANCD2 expression. These findings agree with our concurrent 
immunohistochemistry data where we observed a lack of FANCD2 protein expression in T-
OED compared with NT-OED lesions. 
The direct evaluation of the DNA sensing-signalling-damage repair cascade in OED has not 
been previously reported, although there is recent evidence that individuals with reduced, 
systemic, double strand break repair capacity are more prone develop to head and neck 
cancer (38). It has been suggested that activation of DNA damage response might be 
protective in the early stages of oral carcinogenesis, but progressive 
deregulation over time could eventually result in the failure to suppress malignant 
transformation(170). The results of the current study indicate that additional evaluation of 
these pathways is worthwhile to understand their capability to predict malignant 
transformation in OED at the initial diagnostic biopsy, especially as time to transformation 
may be as long as 7 years (20, 97).  Loss of heterozygosity (LOH) status  at putative tumour 
suppressor gene loci (3p14, 9p21, 9p22 and 17p13) is currently the most reliable predictor in 
malignant transformation in OED (79, 171, 172) and there is evidence to suggest that LOH is 
secondary to homologous recombination deficiency/DNA damage repair deficiencies at 15 
cancer sites, including head and neck squamous cell carcinoma (173), indicating a possible 
link with the current data.  
 
In the process of validating the FANCD2-OED Risk score, a multi-centred setting with larger 
sample size would be desired, to control for as many variables as possible matched for 
smoking, clinical appearance, age and management (surveillance vs excision). This would with 
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the numbers needed to treat analysis inform the sensitivity and specificity requirements of 
the potential for the FANCD2-OED Risk score to serve as a potential biomarker for malignant 
transformation in OED(174).  This should explore possibilities of refining the processes 
presented in this study, to streamline the diagnostic pathway so that clinical application 
would be feasible and cost effective. It remains to be seen if the FANCD2-OED Risk score 
could be more accurate in the prediction of malignant transformation when compared to loss 
of heterozygosity(175), or perhaps they could be utilised jointly.  This could inform the 
development of future novel treatment strategies in the management of OED. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
Chapter 7 Conclusion: Proposals for the future management of oral 
epithelial dysplasia - striving for a personalised approach 
 
There has been more clarity over the last decade in the high-risk features of OED based on 
clinical presentation. These include lateral tongue subsite and/or floor of mouth(62-64, 97), 
female gender(10), longer duration of lesion(9, 18), idiopathic leukoplakia(non-smokers) (9, 
18, 97), , size >200mm(21, 56, 65, 97), non-homogenous appearance(9, 21, 97), higher grade 
of dysplasia(10, 20, 66, 97), verrucous subtype(5, 9, 67, 68) and the presence of multiple 
lesions(69). Intervention to date consists of primary surgical excision or conservative clinical 
surveillance, as systemic or topical therapies have not been adopted widely or shown to be 
effective(16, 149, 176, 177). Management of patients with oral epithelial dysplasia should 
incorporate be primary/secondary prevention and patient education around the role of 
tobacco and/or alcohol in carcinogenesis(141, 178). Laser surgical excision has been the more 
widely adopted practice in general as it offers intraoperative advantages in terms of visibility 
and fine precision, when compared to cold steel. It also offers better local control when 
compared with laser ablation and allows for histopathological evaluation of the entire 
resected lesion which in some occasions may harbour subclinical occult early squamous cell 
carcinoma and in larger lesions, there could be heterogeneity in the severity of dysplasia 
grade. The latter factors could impact on patient prognosis and regularity at which patients 
are followed up. There is emerging evidence that the risk of malignant transformation could 
be lower in patients who have their OED excised compared to those in which the lesions are 
managed conservatively(20, 71).  The preceding chapters have demonstrated that in the 
management of OED management of high-risk patients/lesions within a MDT setting can be 
justified by the treatment outcomes within the context of early detection of malignant 
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transformation, simpler treatment modalities and excellent survival outcomes(100). Expert 
guidance derived from local outcomes(76, 97, 100) provides the basis for a clinical 
management and surveillance protocol(179). These clinical determinants are of immense 
value in guiding the selection of management strategies, however remains mainly 
retrospective and have been based on outcomes in single centres. The availability of a 
molecular indicator for underlying deficiencies in DNA damage repair through the FA 
pathway as demonstrated through the proof of concept/pilot study in this cohort based upon 
the initial biopsy of OED following presentation offers the opportunity to combine the clinical 
and molecular determinants of malignant transformation on an individual basis. Due to the 
small sample size in the reported series within this thesis, the proposal for a multi-centre 
study which allows for matching/controlling of clinical factors such as smoking history, 
gender, site, size and appearance of lesion would enable more accurate interpretation of 
findings and allow for the them to be applied to the wider population. Further options for 
progress lie in the potential for less invasive methods of sampling the oral mucosal lesions 
e.g. oral scrapes or brush biopsies instead of an incisional biopsy, or surrogate sampling such 
as utilisation of salivary samples (containing oral epithelial cells). This has been piloted in a 
selected group of patients and there was very close correlation of FANCD2 and related 
protein expression when compared with the blots obtained from proteins extracted from 
cores of archival FFPE (Gupta et. al – unpublished data).  
The practice of Oral and Maxillofacial Surgery is undergoing structural change within the UK 
and it would be foreseeable that in the coming decade, further centralisation of services will 
occur especially where multidisciplinary, subspecialty and/or translational services are 
involved(180). There would be potential for the relevant specialty associations i.e. British 
Association of Oral and Maxillofacial Surgeons, British Society of Oral Medicine and The 
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Pathological Society of Great Britain and Ireland, in collaboration with NHS Improvement, to 
formalise a registry for oral epithelial dysplasia in order that national level data can be 
collated to form sufficient data to progress understanding of the condition especially in 
relation to malignant transformation as this would be in line with the NHS 10-year plan to 
improve early diagnosis of oral cancer and utilise large datasets (clinical and molecular) to 
formulate artificial intelligence supported algorithms in formulation of personalised 
management strategies. There is potential for such a registry to inform the duration and 
interval of follow-up. Utilised in combination with molecular prognosticators, it could help 
risk stratification of patients so that high risk patients can be reviewed in tertiary 
multidisciplinary clinics and lower risk patients could be managed in ‘spoke’ secondary care 
centres or in the primary care within the context of a managed clinical network. 
Several chemoprevention trials have unfortunately not demonstrated significant success in 
the management of oral lesions with malignant potential(181-183). The clinical outcomes 
reported within this thesis(97) and the reported reduction in the risk of smoking-related head 
and neck cancer in a cohort of USA war veterans(184) has in part led to the conception of the 
SAVER (Sodium Valproate for Epigenetic Re-programming in Management of High Risk Oral 
Epithelial Dysplasia) trial: a randomised, double blind, placebo controlled clinical trial with 
embedded mechanistic and feasibility studies, in the UK and Ireland.  
 
Further work 
 
The next phase in advancement in the understanding and management oral dysplasia 
requires more collaborative efforts on a national/multi-national level, to capitalise on the 
information technology available in capturing large clinical datasets which could then be 
112 
 
correlated to translational elements where the support exists. A multidisciplinary and 
multiprofessional initiative will be required to ensure meaningful engagement of clinicians 
involved in the diagnosis, management and follow-up of OED within the primary, secondary 
and tertiary care sectors. The healthcare infrastructure currently in place requires important 
but minor enhancements which would uniquely position the UK National Health Service to 
develop a prevention and early detection collaborative network similar to that which exists in 
British Columbia(62). This should aid early detection of oral squamous cell carcinoma which 
arise from oral epithelial dysplasia. Less invasive methods for the diagnosis and clinical 
surveillance of OED needs to be developed to reduce the morbidity which might arise from 
the need for multiple (interval) incisional biopsies. Techniques to improve the diagnostic 
accuracy of less invasive sampling such as oral scrapes or brush cytology will need to be 
developed. The role of surrogate sampling from saliva samples and how this can be utilised to 
allow early diagnosis of OED/OSCC and in the follow-up of these patients remain areas of 
potential research which has yet to be fulfilled. 
Outcome of existing chemoprevention studies should emerge within the next decade to 
inform clinicians with regard to the viability of pharmaceutical primary prevention for oral 
cancer and/or regression of oral epithelial dysplasia. Mechanistic studies would have been 
embedded within these trials to investigate and validate the known molecular determinants 
of malignant transformation in oral dysplasia(79, 83, 185) against patient and 
clinicopathological characteristics and management outcomes. In the surgical management 
of OED, utility of new technologies such as visual/optical aids (114, 186) and intelligent 
scalpel/laser technologies utilising desorption electrospray ionisation mass 
spectrometry(DESI-MS) (187, 188) has the potential to improve the completeness of excision 
of OED. This allows mass spectrometry testing of aspirated tissue plumes intraoperatively, 
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potentially allowing precision surgical excision with preservation of vital normal structures in 
the oral cavity to preserve and optimise residual function.  
The proposed combined approach in future research and innovation in the management of 
OED adopts a holistic approach to ensure that the delivery of information-based 
management algorithm is combined with translational initiatives which would feedback into 
the process of patient care, and refinement of treatment methods with new emerging 
technologies to reduce morbidity, enhance patient outcomes and quality of life. 
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A, Field JK, Shaw RJ. Response to Oral epithelial dysplasia in oral submucous 
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2. Field EA, McCarthy CE, Ho MW, Rajlawat BP, Holt D, Rogers SN, Triantafyllou 
A, Field JK, Shaw RJ. The management of oral epithelial dysplasia: The 
Liverpool algorithm. Oral Oncol. 2015 Oct;51(10):883-7 
3. Ho MW. Patients with both oral leukoplakia and oral submucous fibrosis had a 
higher rate of malignant transformation compared to patients with oral 
leukoplakia or oral submucous fibrosis alone. J Evid Based Dent Pract. 2013 
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4. Ho MW, Field EA, Field JK, Risk JM, Rajlawat BP, Rogers SN, Steele JC, 
Triantafyllou A, Woolgar JA, Lowe D, Shaw RJ. Outcomes of oral squamous cell 
carcinoma arising from oral epithelial dysplasia: rationale for monitoring 
premalignant oral lesions in a multidisciplinary clinic. Br J Oral Maxillofac Surg. 
2013 Oct; 51(7):594-9. PubMed PMID: 23601832.  
5. Ho MW, Risk JM, Woolgar JA, Field EA, Field JK, Steele JC, Rajlawat BP, 
Triantafyllou A, Rogers SN, Lowe D, Shaw RJ. The clinical determinants of 
malignant transformation in oral epithelial dysplasia. Oral Oncol. 2012 Oct; 
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Book chapter: 
 
• Book chapter - Transoral Laser Microsurgery of Benign and Malignant Lesions 
of the Upper Aerodigestive Tract: CO2 laser in the management of lesions with 
malignant potential in the Oral Cavity (Thieme) MW Ho and RJ Shaw 2015. 
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Oral presentations/abstracts and posters from doctorate  
Invited faculty/lectures 
 
• Course organiser/director and faculty: Yorkshire Oral Lesions with Malignant 
Potential Study Day (multidisciplinary faculty and multi-specialty audience), 23 June 
2017 
• Oral dysplasia: update and review of evidence in the literature 
• Oral dysplasia: translational science, evidence in the literature and 
local experience 
• Oral dysplasia: role of the multidisciplinary clinic and proposal for 
minimum dataset 
 
• Current evidence for management of oral epithelial dysplasia: Yorkshire OMFS 
Specialty Registrar Regional Study Day, May 2016 
 
• The role of double strand DNA break repair regulation in malignant 
transformation of Oral Dysplasia  
• 6th International Meeting for Regional and Targeted Therapies for Cancer, 
Zhongshan Hospital, Shanghai, China November 2014 
 
Oral Peer-Reviewed Abstracts 
 
i. International meetings: 
 
• Evaluation of the DNA damage repair pathway through oral epithelial 
dysplasia scrapes: its role in the determination of malignant transformation (Cancer 
Biology) Michael Ho, Mark Ryan, Juhi Gupta, Asterios Triantafyllou, Janet Risk, Richard 
Shaw, James Wilson 
o American Head and Neck Society: 9th International Conference for Head and 
Neck Cancer, Seattle – July 2016 
 
• The clinical determinants of malignant transformation in oral epithelial 
dysplasia. Ho MW, Risk JM, Woolgar JA, Shaw RJ et al. 
o American Head and Neck Society: 8th International Conference for Head and 
Neck Cancer, Toronto – July 2012 
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ii. National meetings: 
 
• Management of Proliferative Verrucous Leukoplakia: justification for a 
conservative approach – E Okoturo et. al (University of Liverpool) 
o BAOMS, Birmingham June 2017 
 
• Evaluation of the DNA damage repair pathway through oral epithelial 
dysplasia scrapes: its role in the determination of malignant transformation. M. Ho · J. 
Gupta · J. Risk · A. Triantafyllou · R. Shaw · J. Wilson 
o BAOMS, Liverpool July 2015 
 
• The role of ATR-Fanconi Anaemia pathway in malignant transformation of oral 
epithelial dysplasia. Ho MW, Triantafyllou A, Risk JM, Shaw RJ and Wilson JB. 
o BAOMS, Edinburgh July 2014 
 
• The clinical determinants of malignant transformation in oral epithelial 
dysplasia. Ho MW, Risk JM, Woolgar JA, Rogers SN, Shaw RJ et al.  
o BAOMS ASM, London, June 2012 
 
Poster presentations 
 
• Evaluation of outcomes of proliferative verrucous leukoplakia in Leeds Dental 
Institute. T Austin, T Wei, P Chengot and MW Ho 
o BAOMS, Durham June 2018 
 
 
• Transoral laser resection of oral squamous cell carcinoma and oral 
premalignant lesions – complications, morbidity and outcomes (2003-2014). OP 
Krishnan, C Wan, J Johnson, TA Boye, DA Mitchell, DN Sutton and MW Ho 
o BAHNO, London, April 2015 
 
• The role of ATR-Fanconi Anaemia pathway in malignant transformation of oral 
epithelial dysplasia. Ho MW, Triantafyllou A, Risk JM, Shaw RJ and Wilson JB. 
o ECHNO, Liverpool, April 2014 
o BAOMS, Edinburgh July 2014 
o NCRI Cancer Conference, Liverpool, November 2014 
 
• The clinical determinants of malignant transformation in oral epithelial 
dysplasia. Ho MW, Risk JM, Woolgar JA, Rogers SN, Shaw RJ et al. 
o ECHNO, Poznan, Poland, April 2012 
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o BAHNO Annual Meeting, London, April 2012 
o British Society of Oral Medicine ASM, Liverpool, May 2012 
 
